



EIKO LIFESCIENCES LIMITED

F E E L T H E C H E M I S T R Y

Ref. No.: NIDL/BSE/2021-22/15

Dated: 26th August 2021

To,
Corporate Services Department,
BSE Limited, P J Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.
BSE Scrip Code: EIKO 540204

Sub: Notice of 44th AGM and Annual Report 2020-21

Ref: Eiko Lifesciences Limited

BSE Scrip Code: EIKO 540204

Dear Sir,

Pursuant to Regulation 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached Annual Report for the F.Y. 2020-21 along with the Notice of the 44th Annual General Meeting to be held on Tuesday, 28th September 2021 at 4.30 P.M. IST through Video Conferencing ("VC")/ Other Audio-Visual Means ("OAVM") without the physical presence of the Members.

This is in compliance with General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020 and 20/2020 dated May 5, 2020 and January 13, 2021 issued by Ministry of Corporate Affairs ("MCA Circulars") and other applicable provisions of the Companies Act, 2013 and Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 ("said SEBI Circular") issued by the Securities and Exchange Board of India and relevant provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In accordance with the aforesaid MCA Circulars and SEBI Circular, the Annual Report together with the Notice of the AGM is being dispatched only by electronic mode to those Shareholders whose email addresses are registered with the Company/ Depository Participants.

Additionally, the notice of the 44th AGM and Annual Report for the Financial Year 2020-21 can also be downloaded from website of the company i.e., www.narendrainvestment.com

Kindly take the above on record.

Thanking you.

Yours Sincerely,

For **EIKO LIFESCIENCES LIMITED**

Avi Mundecha
Company Secretary
ACS-65529



EIKO LIFESCIENCES LIMITED

FEEL THE CHEMISTRY



44TH ANNUAL REPORT
FY 2020-21

NARENDRA INVESTMENTS (DELHI) LIMITED

NARENDRA INVESTMENTS (DELHI) LIMITED

NARENDRA INVESTMENTS (DELHI) LIMITED

NARENDRA INVESTMENTS (DELHI) LIMITED

NARENDRA INVESTMENTS (DELHI) LIMITED

NARENDRA INVESTMENTS (DELHI) LIMITED

NARENDRA INVESTMENTS (DELHI) LIMITED

NARENDRA INVESTMENTS (DELHI) LIMITED

EIKO LIFESCIENCES LIMITED

EIKO LIFESCIENCES LIMITED

EIKO LIFESCIENCES LIMITED

EIKO LIFESCIENCES LIMITED

EIKO LIFESCIENCES LIMITED

EIKO LIFESCIENCES LIMITED

EIKO LIFESCIENCES LIMITED

EIKO LIFESCIENCES LIMITED

EIKO LIFESCIENCES LIMITED



CONTENTS

Corporate Information	2
Notice of Annual General Meeting	3
Director's Report	14
Secretarial Audit Report	31
Corporate Governance Report	36
Management Discussion and Analysis	47
Independent Auditor's Report	49
Balance Sheet	57
Statement of Profit and Loss	58
Statement of Cash Flows	59
Statement of Changes in Equity	60
Notes	61

IMPORTANT COMMUNICATION TO SHAREHOLDERS

The Ministry of Corporate Affairs (MCA) has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliance by the companies and has issued circulars stating that service of notice/documents including Annual Report can be sent through e-mail to the Shareholders. Further, in compliance with the provisions of the Companies Act, 2013, the Rules framed thereunder, and the recent Circulars issued by the Ministry of Corporate Affairs (MCA) and the Securities and Exchange Board of India (SEBI), electronic copies of the Notice of the 44th (Forty-fourth) Annual General Meeting (AGM) and the Annual Report for the Financial Year 2020-21 will be sent to all the Shareholders whose e-mail addresses are registered with the Company/Depository Participant(s). Shareholders may note that the Notice of the AGM and Annual Report 2020-21 will also be available on the Company's website (at www.narendrainvestment.com), on the websites of the Stock Exchange where the Equity Shares of the Company are listed, i.e., BSE Limited (at www.bseindia.com) and on the website of Central Depository Services (India) Limited (CDSL) (at www.evoting.com)



CORPORATE INFORMATION

BOARD OF DIRECTORS

LAXMIKANT RAMPRASAD KABRA
CHAIRMAN & NON-EXECUTIVE DIRECTOR

UMESH RAVINDRANATH MORE
WHOLE TIME DIRECTOR

MANDAR KAMALAKAR PATIL
INDEPENDENT DIRECTOR

BHAVESH DHIRAJLAL TANNA
NON-EXECUTIVE DIRECTOR

RAJKUMAR GOVINDAS BAHETI
INDEPENDENT DIRECTOR

KAJAL DHANPATRAJ KOTHARI
INDEPENDENT DIRECTOR

REGISTRED OFFICE

604, Centrum, Opp. TMC Office Near
Satskar Grande Hotel, Wagle Estate Thane
400604

REGISTRAR & SHARE TRANSFER AGENTS:

Bigshare Services Pvt. Ltd.
1st Floor, Bharat Tin Works Building, Opp.
Vasant Oasis, Makwana Road, Marol,
Andheri (East), Mumbai, Maharashtra-
400059
Email Id: investor@bigshareonline.com
Website: www.bigshareonline.com

STATUTORY AUDITORS:

M/s. Thanawala & Company
Chartered Accountants

SECRETERIAL AUDITORS

Shravan A. Gupta & Associates
Company Secretary

COMPANY SECRETARY

Avi Mundecha

CFO

Tejas Arun Deherkar

BANKERS

ICICI Bank

44TH ANNUAL GEENRAL MEETING

Date: 28th September 2021

Day: Tuesday

Time: 4:30 PM

Place: Video Conferencing



NOTICE OF THE 44TH ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the 44th (Forty-four) Annual General Meeting (“AGM”) of Members of Eiko LifeSciences Limited (“Company”) [Formerly known as Narendra Investments (Delhi) Limited] will be held on **Tuesday, 28th day of September, 2021 at 4.30 P.M.(IST)** through Video Conference (“VC”)/Other Audiovisuals Means (“OAVM”), for which purpose the Registered Office of the Company situated at 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate Thane 400604 shall be deemed as the venue for the Meeting and the proceedings of the AGM shall be deemed to be made thereat, to transact the following business:

ORDINARY BUSINESS:

1. **To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March 2021 together with the Reports of the Board of Directors and Auditors thereon.**

To consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March 2021 including the Audited Balance Sheet as of 31st March 2021 and the Statement of Profit and Loss and Cash Flow for the year ended on that date and the Reports of the Directors and the Auditors thereon.

2. **Re-appointment of Mr. Laxmikant Kabra as a “Director”, liable to retire by rotation, who has offered himself for re-appointment:**

To appoint a director in place of Mr. Laxmikant Kabra (DIN: 00061346), who retires by rotation and being eligible, offers himself for re-appointment.

The members are requested to consider and if thought fit, to pass the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 152 and other applicable provisions of the Companies Act, 2013, the approval of the Shareholders of the Company be and is hereby accorded to the re-appointment of Mr. Laxmikant Kabra [Director

Identification Number (DIN): 00061346] as a “Director”, who shall be liable to retire by rotation.”

3. **To appoint an Auditor and to fix their remuneration:**

To consider and thought fit, to pass with or without the modification(s), the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of section 139, 142, 143 and other applicable provisions of the Companies Act, 2013, if any, read with Companies (Audit and Auditor) Rules, 2014, including any statutory enactment or modification(s) thereof, the consent of members be and is hereby accorded to appoint M/s. Thanawala & Company, Chartered Accountants, having FRN.: 110948W, as Statutory Auditors of the Company for the period of five Financial Years starting FY 2021-22, who shall hold the office from the conclusion of this Annual General Meeting till the conclusion of the Annual General Meeting of the Company to be held in year 2026 at such remuneration as may be mutually agreed between the Board of Directors and above named Auditors, in addition to the re-imbursalment of applicable taxes and actual out of pocket and travelling expenses incurred in connection with the audit and billed progressively.”

“RESOLVED FURTHER THAT Shri Laxmikant Kabra, Director & Chairman and/ or Avi Mundecha, Company Secretary of the Company be and is hereby authorized to do all such acts, deeds and things as may be required to give effect to the above-mentioned resolution”.

SPECIAL BUSINESS:

4. **Change in designation of Mr. Umesh Ravindranath More (DIN: 09044162) from Director (Executive Category) to Whole time Director, effective from August 17, 2021**

To consider and if thought fit, to pass, with or without modification(s), the following resolution as Special Resolution:

“RESOLVED THAT in partial modification of the earlier resolution approved by the shareholders on December 15, 2020, vide remote E-voting, Mr. Umesh Ravindranath More (DIN: 09044162), who was appointed as Director in the Executive Category of the



Company for a period of five years from November 12, 2020, to November 11, 2025., be and is hereby re-designated as Whole-Time Director of the Company, effective from **August 17, 2021**.

RESOLVED FURTHER THAT except for the change in designation mentioned above, all other terms and conditions of his appointment as approved by the shareholders remain unchanged.”

5. Change in designation of Mr. Bhavesh Dhirajlal Tanna (DIN: 03353445) from Managing Director to Non-Executive Director, effective from August 17, 2021

To consider and if thought fit, to pass, with or without modification(s), the following resolution as Special Resolution:

“**RESOLVED THAT** pursuant to the provision of section 152 of the Companies Act, 2013 and other applicable provision, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof for the time being in force) and rules and regulations made thereunder, approval of members me and is hereby accorded to change in designation of Mr. Bhavesh Dhirajlal Tanna, from Managing Director to Non-Executive Director, liable to retire by rotation of Directors, effective from **August 17, 2021**, on such terms and conditions as mentioned in appointment letter issued to him.

RESOLVED FURTHER THAT Mr. Laxmikant Kabra, Director of the company or Mr. Avi Mundecha, Company Secretary of the Company be and are hereby jointly and/or severally authorized to file the necessary e-forms with Registrar of Companies, Mumbai and to do all such acts and deeds as may be required to give effect to the above resolution.”

6. Approval of Material Related Party Transaction

To consider and if thought fit, to pass with or without modification, the following resolution as an **ORDINARY RESOLUTION**:

“**RESOLVED THAT** pursuant to the provisions of Regulation 23 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), and also

pursuant to the consent of the Audit Committee and the Board of Directors, and subject to such other approvals, consents, permissions and sanctions of other authorities as may be necessary, consent of the Members be and is hereby accorded to the Company to approve all contracts/ arrangements/ agreements/ transactions (including any modifications, alterations, amendments or renewal thereto), with ‘Related Parties’ within the definition of the Companies Act, 2013 and Listing Regulations, as more particularly enumerated in the explanatory statement to the Notice and on such terms and conditions as may be agreed between the Company and such related parties.

RESOLVED FURTHER THAT in this regard, the Board (hereinafter referred to as “the Board” which term shall include any Committee thereof) is hereby authorized to negotiate, finalize, vary, amend, renew, and revise the terms and conditions of the transactions and enter into, sign, execute, renew, modify and amend all agreements, documents and letters thereof, from time to time.

RESOLVED FURTHER THAT the Board be and is hereby authorized to do all such acts, deeds, matters and things and execute all such deeds, documents and writings on an ongoing basis, as may be necessary, pro per or expedient for the purpose of giving effect to the above resolution.”

By order of the board
For Eiko LifeSciences Limited

Registered Office
604, Centrum,
Opp. TMC office, Near Satkar
Grand Hotel, Wagle Estate
Thane West 400 604

Avi Mundecha
Company Secretary
M. No.: 65529



NOTES:

1. The relevant Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 ('Act'), in respect of the Special Business under Item Nos. 3 to 6 set out above and details as required under Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended ('SEBI LODR Regulations'), entered with the Stock Exchanges and Secretarial Standard on General Meetings (SS-2) in respect of the Directors seeking re-appointment at this Annual General Meeting is annexed hereto as "Annexure A". An Explanatory Statement pursuant to Section 102 of the Act setting out material facts relating to Special Businesses to be transacted at the Annual General Meeting is annexed hereto.
2. In view of the outbreak of the COVID-19 pandemic, social distancing norms to be followed and the continuing restriction on movement of persons at several places in the country and pursuant to General Circular Nos. 14/2020, 17/2020 and 20/2020 dated April 08, 2020, April 13, 2020 and May 05, 2020 respectively, and also Circular 02/2021 dated January 13, 2021 issued by the Ministry of Corporate Affairs ("MCA Circulars") and Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 and Circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021 issued by the Securities and Exchange Board of India ("SEBI Circulars"), and in compliance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), the 44th (Forty Fourth) Annual General Meeting of the Company is being convened and conducted in accordance with the aforesaid MCA Circulars and SEBI Circulars through Video Conferencing/ Other Audio Visual Means ("VC/OAVM") facility, which does not require physical presence of members at a common venue. Hence, Members can attend and participate in the ensuing AGM through VC/OAVM. The registered office of the Company shall be deemed to be the venue for the AGM. The procedure for participating in the AGM through VC/OAVM is explained hereunder and is also available on the website of the Company at www.narendrainvestment.com.
3. Since this AGM is being held pursuant to the MCA Circulars through VC/OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence the Proxy Form, Attendance Slip and Route Map are not annexed to this Notice.
4. Corporate Shareholders intending to appoint their Authorized Representative(s) to attend the AGM, pursuant to Section 113 of the Companies Act, 2013, are requested to send to the Scrutinizer Mr. Shravan Gupta, Practicing Company Secretary (Membership No.27484), CDSL and the Company, a scanned certified true copy of the Board Resolution with at tested specimen signature of the duly authorized signatory(ies) who are authorized to attend and vote on their behalf at the AGM. The said Resolution/Authorization shall be sent to the Scrutinizer by-mail through its registered email address to cs.shravangupta@gmail.com with a copy marked to www.evotingindia.com and investor.relations@eikolifesciences.com
5. In case of joint holders attending the AGM, only such joint holder who is higher in the order of names will be entitled to vote.
6. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
7. The Register of Members and Share Transfer Books of the Company will remain closed from Wednesday, 22nd September 2021 to Tuesday, 28th September 2021 (both days inclusive) for the purpose of Annual General Meeting.
8. Shareholders are requested to intimate changes, if any, pertaining to their name, postal address, e-mail address, telephone / mobile numbers, Permanent Account Number (PAN), bank details including change in bank account number, IFSC Code, MICR Code, name of bank and branch details, to their Depository Participant(s) (DPs) in case the shares are held by them in electronic form and to Bigshare Services Private Limited, Registrar and Share Transfer Agent of the Company ("Bigshare") in case the shares are held by them in physical form.



Members who are holding shares in demat mode are requested to notify any change in their residential address, bank account details and/ or email address immediately to their respective Depository Participants.

9. In accordance with, the General Circular No. 20/2020 dated 5th May, 2020 issued by the Ministry of Corporate Affairs (MCA) and Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated 12th May, 2020 issued by the Securities and Exchange Board of India (SEBI), the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2021, including Report of Board of Directors, Statutory Auditors' Report or other documents required to be attached therewith and the Notice of AGM are being sent through electronic mode to Members whose e-mail address is registered with the Company or the Depository Participant(s) or Bigshare.
10. Members are requested to support "Green Initiative" by registering / updating their e-mail address(es) with the Depository Participant(s) (in case of Shares held in dematerialized form) or with Bigshare (in case of Shares held in physical form). Pursuant to Sections 101 and 136 of the Companies Act, 2013 read with the relevant Rules framed thereunder, companies can serve Annual Reports and other communications through electronic mode to those Members who have registered their e-mail address either with the Company or with the Depository Participant(s). Members holding shares in dematerialized form are requested to register (or update, in case of any change) their e-mail address with their Depository Participant(s), if not already registered / updated and Members holding shares in physical form are requested to register (or update, in case of any change) their e-mail address with Bigshare on its website (at www.bigshareonline.com), to enable the Company to send electronic communications.
11. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of contracts or arrangements in which the Directors are interested under Section 189 of the Companies Act, 2013, and all other documents referred to in the Notice and Explanatory Statement will be available for inspection in electronic mode by writing to the Company at its email id : investor.relations@eikolifesciences.com till the date of AGM.
12. Members may also note that the Notice of AGM and the Annual Report for the Financial Year 2020-21 will be available on the Company's website www.narendrainvestment.com, on the websites of the Stock Exchange where the Equity Shares of the Company are listed, i.e., BSE Limited (at www.bseindia.com) and on the website of Central Depository Securities (India) Limited at www.evotingindia.com
13. Members holding shares in physical mode and who have not registered / updated their email addresses with the Company are requested to update their email addresses with the Registrar and Transfer Agents of the Company, viz., Bigshare on its website (at www.bigshareonline.com) along with the copy of the signed request letter mentioning the name and address of the Member, scanned copy of the share certificate (front and back), self-attested copy of the PAN card, and self-attested copy of any document (e.g.: Driving License, Election Identity Card, Passport) in support of the address of the Member. In case of any queries / difficulties in registering the e-mail address, such Members may write to investor@bigshareonline.com. Members holding shares in dematerialized mode are requested to register / update their e-mail addresses with the relevant Depository Participant(s).
14. Shareholders can avail the facility of nomination in respect of shares held by them in physical form, pursuant to the provisions of Section 72 of the Companies Act, 2013 read with the Rules framed thereunder. Members desiring to avail of this facility may send their nomination in the prescribed Form No. SH-13 duly filled in to Bigshare. Members holding shares in electronic form may contact their respective Depository Participants for availing this facility.
15. SEBI has mandated that securities of listed companies can be transferred only in dematerialized form 1st April 2019, except in case of transmission and transposition of securities. In view of the same and to avail various benefits of dematerialization, Shareholders are advised to dematerialize shares held by them in physical form and for ease in portfolio management. Shareholders can



contact the Company or Bigshare for assistance in this regard.

16. Shareholders holding shares in more than one folio in the same name(s) are requested to send the details of their folios along with share certificates to enable the Company to consolidate their holding into one folio.
17. The venue of the AGM shall be deemed to be the Registered Office of the Company at 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate Thane 400604.
18. Detailed instructions for remote E-voting and E-voting during the 44th AGM, both forming part of this Notice, are annexed.
19. **THE INSTRUCTIONS OF SHAREHOLDERS FOR REMOTE E-VOTING AND E-VOTING DURING AGM AND JOINING THE MEETING THROUGH VC/OAVM ARE AS UNDER:**

A. VOTING THROUGH ELECTRONIC MEANS

- a. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs (MCA), the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a Shareholder using remote e-voting system as well as venue voting on the date of the AGM will be provided by CDSL.
- b. The Shareholders who wish to cast their vote by remote e-voting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again, and if casted again, then the same will not be counted.
- c. The remote e-voting period commences on **Saturday, 25th September 2021 (at 9.00 a.m. IST)** and ends on and **Monday, 27th September 2021 (at 5.00 p.m. IST)**. During

this period, the Shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date, i.e., **Wednesday, 22nd September 2021**, may cast their votes by remote e-voting. The remote e-voting module shall be disabled by CDSL for voting thereafter. Once the vote on a resolution is casted by the Shareholder, the Shareholder shall not be allowed to change it subsequently.

- d. The voting rights of Members shall be in proportion to their share in the Paid-up Equity Share Capital of the Company as on the cut-off date i.e., **Wednesday, 22nd September 2021**.
- e. Any person, who acquires Shares of the Company and becomes a Member of the Company after sending of the Notice and holding shares as of the cut-off date, may obtain the login ID and password by sending a request at evoting@nsdl.co.in. However, if he/she is already registered with CSDL for remote e-voting then he/she can use his/her existing User ID and password for casting the vote

B. INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING:

Manner of Voting Electronically using CDSL e-Voting system:

The way to vote electronically on CDSL e-Voting system consists of "Two Steps" which are mentioned below:

Step1:

Log-into CDSL e-Voting system at www.evotingindia.com

Step2:

Cast your vote electronically on CDSL e-Voting system.

- a. Open the internet browser by typing the URL: www.evotingindia.com
- b. Click on Shareholder-Login
- c. If you are already registered with CDSL for e-voting, then you can use your existing user ID and password.
- d. If you are logging in for the first time, please enter the user ID and password provided in the PDF file attached with thee-mail as initial password.



- e. Open email and open attached PDF file with your Client ID or Folio No. as password. The said PDF file contains your user ID and password/PIN for e-voting. Please note that the password is an initial password.
- f. Password change menu will appear on your screen. Change the password with new password do for your choice with minimum 8 digits/characters or combination there-of. Note the new password. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- g. Once thee-voting home page opens, click one-Voting > Active Voting Cycles.
- h. Select "EVEN" (E-Voting Event Number) of Eiko LifeSciences Limited. Now you are ready for e-voting as Cast Vote page opens.
- i. Cast your vote by selecting appropriate option and click on "Submit" and "Confirm" when prompted.
- j. Upon confirmation, the message "Vote cast successfully" will be displayed.
- k. Once you have vote don't here solution, you will not be allowed to modify your vote.

General Guidelines for Shareholders:

- a. Institutional Shareholders (i.e., other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution / Authority letter, etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the **Scrutinizer through e-mail to cs.shravangupta@gmail.com**
- b. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the Downloads Section of www.evotingindia.com or call on toll free number 1800-222-990.

Process for those Shareholders whose Email IDs are not registered with the Depositories, for procuring User ID and Password and Registration of E-mail IDs for E-voting for the Resolutions set out in the Notice of AGM:

- a. In case shares are held in physical mode, please provide Folio No., Name of shareholder, scanned copy of the Share Certificate (front and back), Permanent Account Number (PAN) Card (self-attested scanned copy of PAN card), Aadhaar (self-attested scanned copy of Aadhaar Card) to **Bigshare** on its website at www.bigshareonline.com.
- b. In case shares are held in Demat mode, please provide DPID-CLID (16-digit DPID + CLID or 16-digit Beneficiary ID), Name, client master or copy of Consolidated Account Statement, PAN (self-attested scanned copy of PAN card), Aadhaar (self-attested scanned copy of Aadhaar Card) to your Depository Participant (DP).

Instructions for Members for E-Voting on the day of the AGM: -

- a. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
- b. Only those Shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
- c. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
- d. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

C. INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM:

- a. Members will be provided with a facility to attend the AGM through VC/OAVM through the CDSL e-Voting system. Members may access the same at <https://www.evotingindia.com> under shareholders/ members login by using the remote e-voting credentials. The link for VC/OAVM will be available in shareholder/members login where the EVEN of Company will be displayed. Please note that the Members who do not have the User ID and Password for e-Voting or have forgotten the User




ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the Notice to avoid last minute rush. Further, Members can also use the OTP based login for logging into the e-Voting system of CDSL.

- b. The Members can join the AGM in the VC/OAVM mode 30 (thirty) minutes before and after the scheduled time of commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
- c. Members are encouraged to join the Meeting through Laptops for better experience.
- d. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the Meeting.
- e. Please note that participants connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
- f. Shareholders, who would like to express their views / have questions, may send their questions in advance mentioning their name Demat account number/folio number, email id, mobile number at investor.relations@eikolifesciences.com. The same will be replied by the Company suitably, either in advance or at the time of AGM.
- g. Members who would like to express their views or ask questions during the AGM may register themselves as a speaker by sending their request in advance from their registered e-mail address mentioning their name, DP ID and Client ID/folio number, PAN, mobile number at investor.relations@eikolifesciences.com at least 10 days prior from the date of the meeting. Those Members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.
- h. AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated 8th April 2020 and MCA Circular No. 17/2020 dated 13th April 2020 and MCA Circular No. 20/2020 dated 5th May 2020 also Circular 02/2021 dated January 13, 2021.
- i. Mr. Shravan Gupta, Practicing Company Secretary (Membership No.27484) has been appointed as the Scrutinizer to scrutinize the remote e-voting process and e-voting to be conducted at the AGM, in a fair and transparent manner and he has communicated his willingness to be appointed and will be available for same purpose.
- j. The Results shall be declared not later than 48 (forty-eight) hours from conclusion of the AGM. The Results declared along with the Scrutinizer's Report will be placed on the website of the Company at www.narendrainvestment.com immediately after the Result is declared by the Chairman and will simultaneously be forwarded to BSE Limited and National Stock Exchange of India Limited, where Equity Shares of the Company are listed.
- k. Subject to receipt of requisite number of votes, the Resolutions shall be deemed to be passed on the date of the Meeting, i.e., Tuesday, 28th September 2021.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

Item No. 3

The members of the Company at the Extra Ordinary General Meeting held on December 15, 2020, has approved the appointment of M/s. Thanawala & Company, Chartered Accountants, having FRN.: 110948W as the Statutory Auditors of the Company to fill the casual vacancy caused by the resignation of M/s. A N A M & ASSOCIATES, Chartered



Accountants, and to hold the office of the Statutory Auditors up to the conclusion of 44th Annual General Meeting.

In accordance with section 139(8) of the Companies Act, 2013, the auditor appointed in the Casual vacancy shall hold office till the conclusion of next Annual General Meeting. Therefore, M/s. Thanawala & Company, Chartered Accountants shall hold office only till the conclusion of ensuing Annual General Meeting.

Accordingly, based on the recommendation of the Audit Committee and confirmation received from M/s. Thanawala & Company, Chartered Accountants, having FRN.: 110948W on their eligibility, the Board recommends to the members for the appointment of M/s. Thanawala & Company, Chartered Accountants, as the Statutory Auditors of the Company, who shall hold the office from the conclusion of this Annual General Meeting till the conclusion of the Annual General Meeting of the Company to be held in year 2026 at such remuneration as may be mutually agreed between the Board of Directors and above named Auditors.

Regarding appointment of Statutory Auditors referred to in item no. 3 of the Notice, the brief profile of the Auditors is as under:

M/s. Thanawala & Company, Chartered Accountants, are a fast-growing CA firm offering wide range of services with the mission of growth of our clients as well as our own team.

They provide services in the areas of Audit and Assurance, Taxation, Accounting, Corporate Finance, Direct and Indirect Taxation, Internal Audits, Corporate and Allied Laws.

None of the Directors / Key Managerial Personnel of the Company / their relatives are in any way concerned or interested, financially or otherwise, in the resolution set out at Item No. 3 of the Notice. The Board recommends the Resolution set forth at Item No. 3 of the Notice for approval of the members as a Ordinary Resolution.

Item No. 4

Change in designation of Mr. Umesh Ravindranath More (DIN: 09044162) from Director (Executive Category) to Whole time Director, effective from August 17, 2021

The shareholders vide special resolution passed through remote E-voting on December 15, 2020, approved the appointment of Mr. Umesh Ravindranath More as Director in Executive Category of the Company for a period of five years w.e.f. November 12, 2020, to November 11, 2025. The terms and conditions of his appointment, including remuneration were approved by the shareholders in accordance with the provisions contained in Sections 196, 197, 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013.

Pursuant to the recommendation by the Nomination and Remuneration Committee, the Board of Directors at their meeting held on August 25, 2021, has re-designated Mr. Umesh Ravindranath More, as the Whole-time Director of the Company w.e.f. August 17, 2021. Since, the designation of Mr. Umesh Ravindranath More, was specifically mentioned as Executive Director in the earlier resolution dated December 15, 2020, approved by the shareholders, this resolution is being proposed to partially modify the same. Except for the change in designation, all other terms and conditions as approved by the shareholders on December 15, 2020, remain unaltered.

Save and except, Mr. Umesh Ravindranath More to whom the resolution relates along with his relatives, none of the Directors/ Key Managerial Personnel of the Company/their relatives is in any way, financially or otherwise, concerned or interested in this Resolution.


The Board recommends the Resolution set forth at Item No. 4 of the Notice for approval of the members as a Special Resolution.

Item No. 5

Change in designation of Mr. Bhavesh Dhirajlal Tanna (DIN: 03353445) from Managing Director to Non-Executive Director, effective from August 17, 2021

The members are apprised that Mr. Bhavesh Dhirajlal Tanna who was appointed as Managing Director of the Company for a period of five years w.e.f. 23rd April 2019, to 22nd April 2024, has shown his willingness to act as Managing Director of the company.

The Board of Directors at their meeting held on August 25, 2021, noted the request received from Mr. Bhavesh Dhirajlal Tanna about his desire to step down as the



Managing Director of the Company, due to certain personal reasons.

Pursuant to the recommendation by the Nomination and Remuneration Committee, the Board of Directors at their meeting held on August 25, 2021, has approved the change in designation Mr. Bhavesh Dhirajlal Tanna, from Executive Director to Non-Executive Director of the company on terms and conditions as mentioned in appointment letter w.e.f. August 17, 2021.

Hence, the Committee & the Board have proposed to appoint him as Non-Executive Director of the company. The appointment of Mr. Bhavesh Dhirajlal Tanna as such shall take effect from August 17, 2021 and requires the approval of the Shareholders of the company by way Ordinary resolution passed at the general meeting as per the provision of section 152 and other applicable provisions, if any of the Companies Act, 2013.

Based on the recommendation of the Nomination & Remuneration Committee & the Board, the matter is recommended to the shareholders for their approval for change in designation of Mr. Bhavesh Dhirajlal Tanna, from Managing Director to Non-Executive Director of the company on such terms and conditions as mentioned in the Letter of Appointment.

None of the Directors and/or Key Managerial personnel of the company and their relatives, except Mr. Bhavesh Dhirajlal Tanna and their relatives, are in any way concerned or interested in the proposed appointment of Mr. Bhavesh Dhirajlal Tanna as Non-Executive Director of the company.

Item No. 6

Pursuant to the provisions of Section 188 of the Companies Act, 2013 (“the Act”), read with the Companies (Meetings of Board and its Powers) Rules, 2014 (‘Rules’), the Company is required to obtain consent of the Board of Directors and prior approval of the members by way of ordinary resolution in case certain transactions with related parties exceeds such sum as is specified in the said Rules. The aforesaid provisions are not applicable in respect of transactions which are in the ordinary course of business and on arm’s length basis.

However, pursuant to Regulation 23 of the Securities and Exchange Board of India (Listing Obligations and Disclosure

Requirements) Regulations, 2015 (the ‘Listing Regulations’), approval of the members through ordinary resolution is required for all material related party transactions, even if they are entered into in the ordinary course of business and on arm’s length basis. For this purpose, a transaction is considered material, if the transaction/transactions to be entered into individually or taken together with previous transactions during a Financial Year exceed 10% of the annual consolidated turnover of the Company, as per the last audited financial statements of the Company.

The Company proposes to enter into contracts/arrangements with related parties in which Director are interested in financial year 2021-22 as mentioned below, which are in the ordinary course of business and at arm’s length basis. Further, the estimated value of the proposed transaction is likely to exceed 10% of the annual consolidated turnover of the Company for the financial year ended on March 31, 2021, and therefore may exceed the materiality threshold as prescribed under Regulation 23 of the Listing Regulations. Thus, these transactions would require the approval of the Members by way of Ordinary Resolution.



Sr. No.	Name of Related Party	Name of the Directors or Key Managerial Personnel who are related, if any	Nature of Relationship	Nature of transaction	Amount
1.	Laxmikant Ramprasad Kabra	Director of Eiko LifeSciences Limited	Director & Promoter	Unsecured Loan	Up to Rs 5 Crore
2.	Bhavesh D Tanna	Director of Eiko LifeSciences Limited	Director & Promoter	Unsecured Loan	Up to Rs 5 Crore
3.	Lake City Traders Private Limited	Mr. Laxmikant Ramprasad Kabra, Director of the Company and Director of Lake City Traders Private Limited	Director of Lake City Traders Private Limited	Unsecured Loan	Up to Rs 5 Crore
4.	Lenus Finvest Private Limited	Mr. Laxmikant Ramprasad Kabra, Director of the Company and Director of Lenus Finvest Private Limited	Director of Lenus Finvest Private Limited	Unsecured Loan	Up to Rs 5 Crore
5	M/s Urvi Speciality Chemicals	Mr. Umesh More, Director of the Company and Partner of the Urvi Speciality Chemicals	Partner of the Urvi Speciality Chemicals (Partnership firm)	Factory Management fees	Up to Rs 50 lacs
6	Plutus Capital Management LLP	Mr. Laxmikant Ramprasad Kabra, Director of the Company and Designated Partner of Plutus Capital Management LLP	Designated Partner of Plutus Capital Management LLP	Unsecured Loan	Up to Rs 5 Crore

Regulation 23 (7) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 provides that all entities falling under the definition of related parties shall not vote to approve any related party transaction, irrespective of whether the entity is a party to the transaction or not. Therefore, none of the Promoter Group entities holding share(s) will vote on the above Resolution.

The Board considers that the proposed arrangements with the related parties, are in the ordinary course of business.

Except Mr. Laxmikant Kabra, Mr. Bhavesh Tanna and Mr. Umesh More along with their relative none of the Directors and Key Managerial Personnel or their relatives are in any way, concerned or interested, financially or otherwise, in the said resolution.

The Board recommends the Ordinary Resolution as set out in Item No.6 of this Notice for approval of the Members.



ANNEXURE A

BRIEF RESUME OF DIRECTORS SEEKING REAPPOINTMENT AT 44TH ANNUAL GENERAL MEETING OF THE COMPANY

Pursuant to Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Secretarial Standard-2 on General Meetings:

Name of Director	Mr. Laxmikant Kabra (Non-Executive Director)
Director Identification Number (DIN)	00061346
Date of Birth (DD/MM/YYYY)	09/03/1969
Age (in Years)	52
Nationality	Indian
Percentage of shareholding of company	0.52
Qualification	Commerce Graduate and a Member of the Institute of Chartered Accountants of India (ICAI)
Brief Profile and Expertise in Specific Functional Area	Mr. Laxmikant Kabra aged 52 years is Non-Executive Director of the Company and is a Chartered Accountant by profession. He has been associated with the Company as Promoter Director. He has immense knowledge in field of Equity and Private Equity, Taxation, Audit, Business Management, etc. He has handled multiple assignments of fund raising through IPO/ FPO, Business restructuring and transformation, Competition Analysis, Market study and Financial Analysis.
Number of Equity Shares held in the Company	20,000
Number of Board Meetings attended during the Financial Year 2020-21	6
List of other Directorships held in Public Limited Companies	AMARNATH SECURITIES LIMITED



BOARD'S REPORT

To,
The Members,
Eiko LifeSciences Limited
(Formerly known as Narendra Investments (Delhi) Limited)
604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel,
Wagle Estate Thane 400604

Your directors have pleasure in presenting the 44th Annual Report together with the audited statement of accounts for the year ended 31st March 2021.

1. FINANCIAL RESULTS

(Amount in ₹)

Particulars	Audited	
	2020-21	2019-20
Profit before Interest, Depreciation and Tax	98,21,174	26,00,344
Finance Cost	8,77,543	6,83,326
Depreciation and Amortization	6,16,284	6,16,284
Profit/(Loss) Before Tax	83,27,347	13,00,734
Provision for taxation	21,84,053	22,788
Profit/(Loss) After Tax	61,43,294	12,77,946
Other Comprehensive Income	8,97,572	-7,29,098
Total Comprehensive Profit for year	70,40,866	5,48,848
Total Comprehensive Profit for year attributable to Non-Controlling Interest	-	-
Earnings per Share (Basic & Diluted)	1.61	0.33

2. OPERATIONS:

The total revenue of the Company for the financial year ended 31st March 2021 has been ₹11,99,05,799/-.

The EBIDTA from normal operation for financial year 2020-21 was ₹98,21,174/- as compared to ₹26,00,344/- in the previous year, registering the rise of about 277.69%.

The result of all the above factors registering the rise in turnover, and the Profit after Tax of the financial year ended 31st March 2021 has been increase by 380.72% to ₹61,43,294/- as against ₹12,77,946/- for the previous year.

3. DIVIDEND:

In view of the fact that, the Company is considering business expansion in the field of Speciality and fine Chemical in the near future, the Company shall retain earnings for funding further growth. The Company is also desirous to exploit the opportunities to undertake suitable projects. Therefore, the Board of Directors (hereinafter referred to as "the Board") has decided not to declare any dividend for the financial year under review.

4. SHARE CAPITAL:

The paid-up equity share capital as on 31st March 2021 was ₹3,82,00,000/- divided into 38,20,000 equity shares of ₹10/ each. During the year under review the company has not made any fresh issue of shares.



5. TRANSFER OF UNPAID/ UNCLAIMED DIVIDEND:

The Company does not have any amount of Unpaid/Unclaimed Dividend which is required to be transferred to the Investors Education & Protection fund as required under Section of the Companies Act 2013. There is no other statutory amount like outstanding unpaid Refund Amount on Share Applications, unpaid interests or principal of Deposits and Debentures, etc. lying with the company which are required to be transferred to Investors Education and Protection Fund.

6. TARNSEFER TO RESERVES:

The Board of Directors have not appropriated and transferred any amount to any reserve and the Board has decided to retain the entire amount in the profit and loss account.

7. CHANGE IN BUSINESS NATURE:

The Company has commenced the new business in the field of Speciality and fine Chemical during the year under review.

8. DEPOSITS:

The Company has not accepted or renewed any amount falling within the purview of provisions of Section 73 of the Companies Act 2013 (“the Act”) read with the Companies (Acceptance of Deposit) Rules, 2014 during the year under review. Hence, the requirement for furnishing of details relating to deposits covered under Chapter V of the Act or the details of deposits which are not in compliance with the Chapter V of the Act is not applicable.

9. COMPLIANCE WITH THE LISTING AGREEMENT:

Company’s shares are listed on BSE Ltd. w.e.f. 13th December’ 2016 and Company has complied with the mandatory provisions of Corporate Governance as stipulated in the Listing Agreement with the Stock Exchange.

10. REPORT ON PERFORMANCE OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURE COMPANIES:

The Company had two Subsidiaries Fudkor India Private Limited (51%) and Vegico Foods Private Limited (100%) till financial year 2019-20. In financial year 2020-21 these two Companies ceased to become Subsidiaries Companies. Hence, your Company did not have any

subsidiary, associate, and joint venture company during the year under review.

11. CHANGE OF NAME:

The name of has changed from Narendra Investments (Delhi) Limited to Eiko LifeSciences Limited with effect from June 24, 2021, i.e., post review period.

12. SIGNIFICANT OR MATERIAL ORDER PASSED BY REGULATORS/COURTS:

During the year under review, there were no significant or material orders passed by the regulators or court or tribunals impacting the going concern status and Company Operations in future.

13. MATERIAL CHANGES AND COMMITMENT AFFECTING FINANCIAL POSITION OF THE COMPANY:

There are no material changes and commitments, affecting financial position of the Company which has occurred between the end of the financial year of the Company i.e., March 31, 2021, and the date of the director report.

14. CORPORATE GOVERNANCE:

As per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Corporate Governance Report with the Auditors’ Certificate thereon are attached and form part of this Report.

15. MANAGEMENT DISCUSSION AND ANALYSIS:

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Management Discussion and Analysis is attached hereto and forms part of this Report.

16. RELATED PARTY TRANSACTION:

Your Company has historically adopted the practice of undertaking related party transactions only in the ordinary and normal course of business and at arm’s length as part of its philosophy of adhering to highest ethical standards, transparency, and accountability.

The particulars of contracts or arrangements with related parties referred to in subsection (1) of section 188 of the Act in the prescribed Form AOC-2 is annexed hereto and marked as **Annexure – “A”** and forms part of this Report.



17. DISCLOSURE OF INFORMATION AS REQUIRED UNDER SECTION 134 (3)(M) OF THE COMPANIES ACT, 2013 (ACT) READ WITH THE COMPANIES (ACCOUNTS) RULES, 2014:

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of The Companies (Accounts) Rules, 2014, is annexed hereto and marked as **Annexure – “B”**

18. ANNUAL RETURN

Pursuant to the provisions of Section 92(3) and 134 (3) (a) of the Act, 2013, the Annual Return for the financial year ended 31st March 2021 is given in **Annexure ‘C’** to this Report. A copy of the Annual Return is also available on the website of the Company- www.narendrainvestment.com

19. AUDITORS & REPORTS:

a. Statutory Auditors:

Pursuant to the provisions of Section 139 of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014, M/s. Thanawala & Company, Chartered Accountants, having FRN.: 110948W, was appointed as Statutory Auditors of the Company, to fill the casual vacancy caused by the resignation of M/s A N A M & Associates, Chartered Accountants, Ahmedabad, who shall office upto the conclusion of the ensuing Annual General Meeting. The consent of the Auditors along with certificate under Section 139 of the Act have been obtained from the Auditors to the effect that their appointment, if made, shall be in accordance with the prescribed conditions and that they are eligible to hold the office of Auditors of the Company.

The Board of Directors of the Company at their meeting held on August 25, 2021, on the recommendation of the Audit Committee, have made its recommendation for the appointment of M/s. Thanawala & Company, Chartered Accountants, having FRN.: 110948W the Statutory Auditors of the Company for an initial term of five years. Accordingly, a resolution, proposing appointment of M/s. Thanawala & Company, Chartered Accountants, having FRN.: 110948W as a Statutory Auditors of the Company for a term of five consecutive

years (i.e.) from the conclusion of 44th Annual General Meeting of the Company till the conclusion of the 49th Annual General Meeting of the Company, subject to ratification of the appointment by the Members at ensuing Annual General Meeting.

The Notes on financial statement referred to in the Auditors’ Report are self-explanatory and do not call for any further comments. The Auditors’ Report does not contain any qualification, reservation, adverse remark or disclaimer.

b. Secretarial Audit:

The Board on the recommendation of the Audit Committee appointed M/s Shraavan A. Gupta & Associates; Company Secretaries in Practice, Mumbai, as Secretarial Auditor to conduct Secretarial Audit of the Company for the Financial Year 2020-21 and their report is annexed hereto and marked as **Annexure “D”**

c. Cost Audit:

Pursuant to the provisions of Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, as amended from time to time, the Company is not required to maintain Cost Records under said Rules.

d. Internal Auditors of the Company:

The Company has adopted an internal control system, commensurate with its size. The Company had appointed M/s S S N R & CO as the Internal Auditor of the Company for Financial Year 2020-21.

There are no adverse remarks by Internal Auditor in the report issued by them for the financial Year end 31st March 2021.

e. Reporting of frauds by statutory auditors:

There were no incidences of reporting of frauds by Statutory Auditors of the Company under Section 143 (12) of the Act read with Companies (Accounts) Rules, 2014.

f. Code for prevention of Insider Trading:

As per Securities and Exchange Board of India (Prohibition of Insider Trading Regulations), 2015, your



Company has adopted an amended Code of Conduct to regulate, monitor and report trading by Designated Persons and their Immediate Relatives under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. This Code of Conduct also includes code of practices and procedures for fair disclosure of unpublished price sensitive information and has been made available on the Company's website.

20. UPDATION OF EMAIL IDS FOR RECEIVING NOTICES / DOCUMENTS IN ELECTRONIC MODE:

Shareholders who have not registered their email addresses with the Company are requested to register their email addresses with the Company to enable the Company to deliver notices /documents through e-mode. Shareholders holding their shares in demat mode also have an option to register their email addresses with their depository, through their depository participant.

21. INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:

The Company maintains adequate internal control systems, which provide, amongst other things, adequate support to all its operations and effectively handle the demands of the Company's financial management systems. The Company has in place effective systems safeguarding the assets and interest of the Company and ensuring compliance with law and regulations. The Company's internal control systems are supplemented by an extensive program of internal audit conducted by an external auditor to ensure adequate system of internal control.

22. DIRECTORS RESPONSIBILITY STATEMENT:

Pursuant to the provisions of Section 134 (5) of Companies Act, 2013, as amended, with respect to the Directors' Responsibility Statement, it is hereby confirmed that:

- i. In the preparation of the accounts for the financial year ended 31st March 2021, the applicable Accounting Standards have been followed along with proper explanation relating to material departures.
- ii. The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give

a true and fair view of the state of affairs of the Company as of 31st March 2021 and of the profit and loss of the Company for the year ended 31st March 2021.

- iii. The Directors have taken proper and enough care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- iv. The Directors have prepared the annual accounts for the financial year ended 31st March 2021 on a going concern basis.
- v. The Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.
- vi. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

23. SECRETARIAL STANDARDS OF ICSI:

Your Company is in compliance with the Secretarial Standards on Meetings of the Board of Directors (SS - 1) and General Meetings (SS - 2) issued by The Institute of Company Secretaries of India and approved by the Central Government.

24. COMMITTEES OF BOARD OF DIRECTORS OF THE COMPANY:

Following are the Committees of Board of Directors of the Company. The Composition of the following Committees are hosted on the website of the Company and details of the following committees has been mentioned in the Corporate Governance Report.

i. Audit Committee:

The Audit Committee of Directors was constituted pursuant to the provisions of Section 177 of the Companies Act, 2013. The composition of the Audit Committee and its meetings during the Financial Year 2020-21 is in conformity with the provisions of the said section.



ii. Nomination and Remuneration Committee:

The Nomination and Remuneration Committee was constituted pursuant to the provision of section 178 of the Act.

The Committee has in accordance with the provisions of sub-section (3) of Section 178 of the Companies Act, 2013, formulated and uploaded on Company website www.narendrainvestment.com, the policy setting out the criteria for determining qualifications, positive attributes, independence of a Director and policy relating to remuneration for Directors, Key Managerial Personnel, and other employees.

iii. Stakeholders Relationship Committee:

The Stakeholders Relationship Committee was constituted pursuant to the provisions of Section 178 of the Act.

iv. Corporate Social Responsibility:

With the enactment of the Companies Act, 2013 and the Companies (Corporate Social Responsibility) Rules, 2014 read with various clarifications issued by the Ministry of Corporate Affairs, every Company having the net worth of ₹500 crores or more or turnover of ₹1000 crores or more net profit of ₹5 crores during any financial year have to spend at least 2% of the average net profit of the Company made during the three immediately preceding financial years. Accordingly, the provision of CSR activities under Companies Act, 2013 do not apply to company.

25. BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONS:

APPOINTMENT

Ms. Kajal Dhanpatraj Kothari:

During the year under review, Ms. Kajal Dhanpatraj Kothari was appointed as the Additional Independent Director of the Company on September 09, 2020.

In the opinion of the Board, Ms. Kajal Dhanpatraj Kothari is a person of integrity. She has relevant experience, expertise, and proficiency to be appointed as an Independent Director on the Board of the Company.

Further, the member of the Company at Annual general Meeting held on September 30, 2020, has appointed her as an Independent Director

Mr. Rajkumar Govindas Baheti:

During the year under review, Mr. Rajkumar Govindas Baheti was appointed as the Independent Director by the members of the Company at their Extra-Ordinary General Meeting held on 31st March 2021.

Mr. Umesh Ravindranath More:

During the year under review, Mr. Umesh Ravindranath More was appointed as the Additional Director in the Executive Category of the Company on November 12, 2020.

In the opinion of the Board, Mr. Umesh Ravindranath is a person of integrity. He has relevant experience, expertise, and proficiency to be appointed as an Independent Director on the Board of the Company.

Further, the member of the Company at Extra-Ordinary General Meeting held on December 15, 2020, has appointed him as a Director in the Executive Category of the Company.

RESIGNATION:

Ms. Archana Dakhale, Independent Director has resigned on September 09, 2020. Except her no other Directors and Key Managerial Personnel of the Company have resigned during the financial year ending 31st March 2021.

RETIREMENT BY ROTATION:

In accordance with the provisions of the Act, none of the Independent Directors is liable to retire by rotation. As per the provisions of Section 152 of the Companies Act, 2013, Mr. Laxmikant Ramprasad Kabra retires by rotation at the ensuing Annual General Meeting and being eligible, offers himself for re-appointment.

Your Directors recommend his approval in accordance with the provisions of the Act and the said Director is not disqualified from being re-appointed as a Director of a Company as per the disclosure received from him pursuant to Section 164(2) of the Act.

APPOINTMENT CRITERIA AND QUALIFICATIONS

The Nomination & Remuneration Committee identifies and ascertain the integrity, qualifications, expertise and experience of the person for appointment as Director, Key Managerial Personnel (“KMP”) or at Senior



Management level and recommend the same to the Board for appointment.

26. MATTERS RELATED TO DIRECTORS:

i. Independent Directors' Declaration:

The Independent Directors have given declarations that they meet the criteria of independence as laid down under Section 149(6) of the Companies Act, 2013.

Pursuant to the Companies (Appointment and Qualification of Directors) Rules, 2014, the Independent Directors are registered with MCA Independent Director's Databank.

ii. Board Evaluation:

In a separate meeting of Independent Directors, performance of non-independent directors, performance of the Board as a whole and performance of the Chairman was evaluated, taking into account the views of executive director. The same was discussed in the Board meeting held subsequently to the meeting of the independent directors, at which Board of Directors carried out an annual evaluation of its own performance, board committee and individual directors pursuant to the provisions of the Act and the Corporate Governance requirements as prescribed by Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The performance of committee was evaluated by the board after seeking inputs from all the directors on the basis of the criteria such as the board composition and structure, effectiveness of board processes, information and functioning etc.

The Board subsequently evaluated its own performance, the working of its Committees (Audit, Nomination and Remuneration and Stakeholders Relationship Committee) and independent Directors (without participation of the relevant Director).

iii. Remuneration Policy:

The Board of Directors has on recommendation of the Nomination & Remuneration Committee framed policy for selection and appointment of Directors, Senior Management and their remuneration which is stated in the Corporate Governance Report.

iv. Number Of Board Meetings:

The Board met 6 (Six) times during the financial year ended 31st March 2021 in accordance with the provisions of the Act, the details of which are given in the Corporate Governance Report.

27. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS BY THE COMPANY:

Pursuant to the provisions of Section 186 of the Act read with The Companies (Meetings of Board and its Powers) Rules, 2014, Loans, guarantees and investments has been furnished in the Notes No. 5 & 6 to Audited financial statement which forms part of the financials of the Company.

28. PARTICULARS OF THE EMPLOYEES:

The requisite details relating to ratio of remuneration, percentage increase in remuneration etc. as stipulated under the above Rules are annexed as **Annexure "E"** to this Report.

29. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

Your Company strongly believes in providing a safe and harassment free workplace for each and every individual working for the Company through various interventions and practices. It is the continuous endeavour of the Management of the Company to create and provide an environment to all its employees that is free from discrimination and harassment including sexual harassment. The Company has adopted a policy on prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder. The Company arranged various interactive awareness workshops in this regard for the employees in the Corporate Office during the financial year.

Following is a summary of sexual harassment complaints received and disposed of during the year:

- No. of complaints received: Nil
- No. of complaints disposed: Nil
- No. of complaints pending: Nil



30. ESTABLISHMENT OF VIGIL MECHANISM:

Pursuant to the provisions of Section 177 (9) of the Act read with Rule 7 of the Companies (Meetings of Board and its Powers) Rules, 2014, and Regulation 22 of SEBI (LODR) Regulations 2015 the Company already has in place “Vigil Mechanism Policy” (Whistle Blower Policy) for Directors and employees of the Company to provide a mechanism which ensures adequate safeguards to employees and Directors from any financial statements and reports, etc.

The employees of the Company have the right/option to report their concern/grievance to the Chairman of the Audit Committee. The Company is committed to adhere to the highest standards of ethical, moral and legal conduct of business operations. The details of the same are mentioned in the Corporate Governance Report.

31. LEGAL AND REGULATORY:

Compliance with laws and regulations is an essential part of your Company’s business operations. We are subject to laws and regulations in diverse areas as product safety, product claims, trademarks, copyright, patents, competition, employee health and safety, the environment, corporate governance, listing and disclosure, employment, and taxes.

Frequent changes in legal and regulatory regime and introduction of newer regulations with multiple authorities regulating same areas lead to complexity in compliance. We closely monitor and review our practices to ensure that we remain compliant with relevant laws and legal obligations.

32. SYSTEM AND INFORMATION:

Your Company’s operations are increasingly dependent on IT systems and the management of information. Increasing digital interactions with customers, suppliers and consumers place even greater emphasis on the need for secure and reliable IT systems and infrastructure, and careful management of the information that is in our possession.

The cyber-attack threat of un-authorized access and misuse of sensitive information or disruption to operations continues to increase. To reduce the impact of external cyber-attacks impacting our business we

have firewalls and threat monitoring systems in place, complete with immediate response capabilities to mitigate identified threats. Our employees are trained to understand these requirements.

33. GENERAL DISCLOSURES:

Your directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

- a. The Company has not issued any shares with differential rights and hence no information as per provisions of Section 43(a)(ii) of the Act read with Rule 4(4) of the Companies (Share Capital and Debenture) Rules, 2014 is furnished.
- b. The Company has not issued any sweat equity shares during the year under review and hence no information as per provisions of Section 54(1)(d) of the Act read with Rule 8(13) of the Companies (Share Capital and Debenture) Rules, 2014 is furnished.
- c. The Company has not issued any equity shares under Employees Stock Option Scheme during the year under review and hence no information as per provisions of Section 62(1)(b) of the Act read with Rule 12(9) of the Companies (Share Capital and Debenture) Rules, 2014 is furnished.
- d. During the year under review, there were no instances of non-exercising of voting rights in respect of shares purchased directly by employees under a scheme pursuant to Section 67(3) of the Act read with Rule 16(4) of Companies (Share Capital and Debentures) Rules, 2014.

34. CAUTIONARY STATEMENT:

Statements in the Board’s Report and the Management Discussion & Analysis describing the Company’s objectives, expectations or forecasts may be forward-looking within the meaning of applicable securities laws and regulations. Actual results may differ materially from those expressed in the statement. Important factors that could influence the Company’s operations include global and domestic demand and supply, input costs, availability, changes in government regulations, tax laws, economic developments within the country



and other factors such as litigation and industrial relations.

35. SHARE TRANSFER SYSTEM:

Presently the Share Transfer documents received by the Company's Registrar and Transfer Agents in physical form are processed, approved, and dispatched within a period of 5 to 15 days from the date of receipt, provided the document receive are complete and the shares under transfer are not under dispute.

ISIN NO:

The Company's Demat International Security Identification Number (ISIN) for its equity shares in NSDL and CDSL is INE666Q01016.

ACKNOWLEDGEMENT:

Your directors would like to express their deep appreciation to employees at all levels for their hard work, dedication, and commitment.

The Board also places on record its appreciation and gratitude for the continued cooperation and support received by your Company during the year from shareholders, investors, bankers, financial institutions, customers, business partners, all regulatory and government authorities, and other stakeholders.

**For and On Behalf of the Board of Directors
Eiko LifeSciences Limited**

Laxmikant Ramprasad Kabra

Chairman

DIN: 00061346

Date: 25.08.2021

Place: Thane



ANNEXURE “A” TO THE DIRECTORS’ REPORT

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm’s length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm’s length basis:

Not Applicable

2. Details of material contracts or arrangement or transactions at arm’s length basis

Particulars	Particulars	Particulars	Particulars
Name(s) of the related party and nature of relationship	Urvi Speciality Chemicals	Chintan Doshi	Tejas Deherkar
Nature of contracts/ arrangements/ transactions	Processing Charges paid	Salary Paid	Salary Paid
Duration of the contracts / arrangements/ transactions	Ongoing	Ongoing	Ongoing
Salient terms of the contracts or arrangements or transactions including the value, if any	Price charged for the transaction shall be based on prevailing market price and shall not be less than price charged for such transaction to unrelated third-party customer having such dealing or transaction with them	-	-
Date(s) of approval by the Board if any	-	-	-
Amount paid as advances if any	NA	NA	NA

For and On Behalf of the Board of Directors

Eiko LifeSciences Limited

Laxmikant Ramprasad Kabra

Chairman

DIN: 00061346

Date: 25.08.2021

Place: Thane



ANNEXURE “B” TO THE DIRECTORS’ REPORT

Disclosure pursuant to Section 134(3)(M) of the Companies Act, 2013 read with rule 8 of the Companies (Accounts) Rules, 2014

A) CONSERVATION OF ENERGY:

Steps taken or impact on conservation of energy	1. Implementation of the measures of Switching of the machineries, light, office equipment during the food break and interval times have resulted in energy saving 2. The Company is constantly reviewing further measures to reduce energy consumption
Steps taken by the company for utilizing alternate sources of energy	Nil
Capital investment on energy conservation equipment’s	Nil

B) TECHNOLOGY ABSORPTION:

Efforts made towards technology absorption	Considering the nature of activities of the Company, there is no requirement regarding technology absorption.
In case of imported technology (imported during the last three years reckoned from the beginning of the financial year):	
• Details of technology imported	Nil
• Year of import	Not Applicable
• Whether the technology has been fully absorbed	Not Applicable
• If not fully absorbed, areas where absorption has not taken place, and the reasons thereof	Not Applicable
• Expenditure incurred on Research and Development	Nil

C) FOREIGN EXCHANGE EARNINGS AND OUTGO:

Particulars	(Amount in ₹)	
	For year ending 31 st March 2021	For year ending 31 st March 2020
Actual Foreign Exchange earnings	4,02,56,944	Nil
Actual Foreign Exchange outgo	Nil	Nil

For and On Behalf of the Board of Directors
Eiko LifeSciences Limited

Laxmikant Ramprasad Kabra

Chairman

DIN: 00061346

Date: 25.08.2021

Place: Thane



ANNEXURE “C” TO THE DIRECTORS’ REPORT

Form MGT 9 - Extract of Annual Return as on financial year ended on 31st March 2021 [Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company Management & Administration) Rules, 2014.]

1. REGISTRATION AND OTHER DETAILS:

CIN	L65993MH1977PLC258134
Registration Date	07.01.1977
Name of Company	Eiko LifeSciences Limited (Formerly known as Narendra Investments (Delhi) Limited)
Category/ Sub-category of the Company	Company having Share Capital Non-Govt Company
Address of the Registered office & contact details	604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate Thane 400604 Email id: investor.relations@eikolifesciences.com Website: www. narendrainvestment.com
Whether listed company	Yes
Name, Address & contact details of the Registrar & Transfer Agent, if any	M/s. Bigshare Services Pvt. Ltd., 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri (East), Mumbai, Maharashtra,400059

2. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

(All the business activities contributing 10 % or more of the total turnover of the company)

Sr. No.	Name and Description of main products / services	NIC Code of the Product/service	% to total turnover of the Company
01	Manufacture of Organic & Inorganic chemicals compounds	20119	100

3. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

During the year under review, your company does not have any holding, subsidiary, and associate Companies

4. SHARE HOLDING PATTERN (EQUITY SHARE CAPITAL BREAKUP AS PERCENTAGE OF TOTAL EQUITY)

i. CATEGORY-WISE SHARE HOLDING

Category of Shareholders	No. of Shares held at the beginning of the year [As on 1-April-2020]				No. of Shares held at the end of the year [As on 31-March-2021]				% Change
	Demat	Physical	Total	% Of Share	Demat	Physical	Total	% Of Share	Demat
A. Promoters									
1. Indian									
a. Individual/ HUF	1,59,140	-	1,59,140	4.17	262000	-	2,62,000	6.86	(2.69)
b. Central Govt	-	-	-	-	-	-	-	-	-
c. State Govt(s)	-	-	-	-	-	-	-	-	-
d. Bodies Corporate	1,00,000	-	1,00,000	2.62	5,54,414	-	5,54,414	14.51	(11.89)
e. Banks / FI	-	-	-	-	-	-	-	-	-
Total shareholding of Promoter (A)	2,59,140	-	2,59,140	6.78	8,16,414	-	8,16,414	21.37	(14.59)
2. Foreign									
B. Public Shareholding									
1. Institutions									
a. Mutual Funds	-	-	-	-	-	-	-	-	-
b. Banks / FI	-	-	-	-	-	-	-	-	-
c. Central Govt	-	-	-	-	-	-	-	-	-
d. State Govt(s)	-	-	-	-	-	-	-	-	-
e. Venture Capital Funds	-	-	-	-	-	-	-	-	-
f. Insurance Companies	-	-	-	-	-	-	-	-	-
g. FIs	-	-	-	-	-	-	-	-	-
h. Foreign Venture Capital Funds	-	-	-	-	-	-	-	-	-
i. Others (specify)	-	-	-	-	-	-	-	-	-
Sub-total (B)(1): -	-	-	-	-	-	-	-	-	-
2. Non-Institutions									
a. Bodies Corporate	5,68,611	-	5,68,611	14.89	7,15,001	-	7,15,001	18.72	(3.83)
b. Individuals									
Individual shareholders holding nominal share capital up to ₹2 lakh	3,58,227	12,100	3,70,327	9.69	3,53,940	12,100	3,66,040	9.58	0.11
Individual shareholders holding nominal share	26,21,922	-	26,21,922	68.64	19,22,545	-	19,22,545	50.33	18.31



capital more than Rs 2 lakh									
Others (specify)	-	-	-	-	-	-	-	-	-
Sub-total (B)(2): -	35,48,760	12,100	35,60,860	93.22	29,91,486	12,100	30,03,586	78.63	14.59
Total Public Shareholding (B)=(B)(1) + (B)(2)	35,48,760	12,100	35,60,860	93.22	29,91,486	12,100	30,03,586	78.63	14.59
C. Shares held by Custodian for GDRs & ADRs	-	-	-	-	-	-	-	-	-
Grand Total (A+B+C)	38,07,900	12,100	38,20,000	100	37,46,800	12,100	38,20,000	100	-

ii. SHAREHOLDING OF PROMOTERS (INCLUDING PROMOTERS GROUP)

Sr No	Shareholder's Name	Shareholding at the beginning of the year (01-04-2020)			Shareholding at the end of the year (31-03-2021)			% Change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged/encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged/encumbered to total shares	
1	Laxmikant Ramprasad Kabra	20,000	0.52	-	20,000	0.52	-	-
2	Bhavesh Dhirajlal Tanna	99,140	2.60	-	2,02,000	5.29	-	-
3	Gaurav Ranjitsingh Chavda	20,000	0.52	-	20,000	0.52	-	-
4	Murlidhar Mohanlal Lakhiani	20,000	0.52	-	20,000	0.52	-	-
5	Lenus Finvest Pvt. Ltd.	1,00,000	2.62	-	5,54,414	14.51	-	-

iii. CHANGE IN PROMOTERS' SHAREHOLDING (INCLUDING PROMOTERS GROUP)

Sr. No.	Name of the Promoter	Shareholding on 1 st April 2020		Increase/ Decrease in Shareholding		Cumulative Shareholding during the year	
		No. of Shares	% of total shares	No. of Shares	% of total shares	No. of Shares	% of total shares
1	Bhavesh Dhirajlal Tanna	99,140	2.60	1,02,860	2.69	2,02,000	5.29
2	Lenus Finvest Private Limited	1,00,000	2.62	4,54,414	11.89	5,54,414	14.51

iv. SHAREHOLDING PATTERN OF TOP TEN SHAREHOLDERS (OTHER THAN DIRECTORS, PROMOTERS AND HOLDERS OF GDRS AND ADRS)

Sr. No.	For Each of the Top 10 Shareholders	Shareholding at the beginning of the year (01-04-2020)		Cumulative Shareholding during the year (31-03-2021)	
		No. of Shares	% of total share	No. of Shares	% of total share
1.	Finsage Capital Services Pvt Ltd	4,30,000	11.26	4,34,009	11.36
2.	Devrath Bakebihari Choursiya	4,00,000	10.47	4,00,000	10.47
3.	Svaks Biotech India Private Limited	-	-	2,11,000	5.52
4.	Sushant Balakrishna Ranpise	1,50,000	3.93	1,50,000	3.93
5.	Vinod Kantilal Rathod	1,50,000	3.93	1,50,000	3.93
6.	Akshay Dharendra Singh	1,20,000	3.14	1,20,000	3.14
7.	Bhavikaben B Patel	1,25,000	3.27	1,01,060	2.65
8.	Roshna Suresh Kataria	1,00,000	2.62	1,00,000	2.62
9.	Saima Jaid Kojar	1,00,000	2.62	1,00,000	2.62
10.	Suresh Jivraj Kataria	1,00,000	2.62	1,00,000	2.62

v. SHAREHOLDING OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
	No. of shares	% of total shares	No. of shares	% of total shares
Mr. Laxmikant Ramprasad Kabra				
At the beginning of the year	20,000	0.52	20,000	0.52
Increase / Decrease in Shareholding during the year	No change During the Year			
At the End of the year	20,000	0.52	20,000	20,000
Mr. Bhavesh Dhirajlal Tanna				
At the beginning of the year	99,140	2.6	99,140	2.6
Increase / Decrease in Shareholding during the year	Increase in Shareholding			
At the End of the year	2,02,000	5.29	2,02,000	5.29
Mr. Tejas Arun Deherkar				
At the beginning of the year	3220	0.084	3220	0.084
Date wise Increase / Decrease in Shareholding during the year	No change During the Year			
At the End of the year	3220	0.084	3220	0.084

vi. INDEBTEDNESS

Indebtedness of the Company, including interest outstanding/accrued but not due for payment.

Particular	Secured Loans	Unsecured Loans	Total
Indebtedness at the beginning of the financial Year			
1. Principal Amount	25,78,671	-	25,78,671
2. Interest due but not paid	-	-	-
3. Interest accrued but not due	-	-	-
Total	25,78,672	-	25,78,672



Change in Indebtedness during the financial year			
Addition	1,56,87,093	-	1,56,87,093
Reduction	-	-	-
Net Change	1,56,87,093	-	1,56,87,093
Indebtedness at the End of the financial Year			
4. Principal Amount	1,82,65,764	-	1,82,65,764
5. Interest due but not paid	-	-	-
6. Interest accrued but not due	-	-	-
Total	1,82,65,764	-	1,82,65,764

5. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

- Remuneration to Managing Director, Whole-time Directors and/or Manager: Nil
- Remuneration to other Directors: Nil
- Remuneration to Key Managerial Personnel other than Md/ Manager/ WTD:

Sr. No.	Particulars	Key Managerial Personnel		Total
		Tejas Deherkar (CFO)	Chintan Doshi (CS)	
1	Gross salary	2,60,000	1,80,000	4,40,000
2	Stock Option	-	-	-
3	Sweat Equity	-	-	-
4	Commission	-	-	-
5	Others, please specify	-	-	-
Total		2,60,000	1,80,000	4,40,000

6. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

There were no penalties, punishments, compounding of offences for the year ending March 31, 2021

For and On Behalf of the Board of Directors
Eiko LifeSciences Limited

Laxmikant Ramprasad Kabra
Chairman
DIN: 00061346

Date: 25.08.2021

Place: Thane

ANNEXURE “D” TO THE DIRECTORS’ REPORT

Details of the Remuneration of Directors, KMP’S And Employees

[Pursuant to Section 197(12) of the Companies Act, 2013 read with Rule 5 (1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

- The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the Financial Year 2020-21, ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the Financial Year 2020-21 and the comparison of remuneration of each Key Managerial Personnel (KMP) against the Performance of the Company are as under:

(Explanation:(i) The expression “median” means the numerical value separating the higher half of the population from the lower half and the median of a finite list of numbers may be found by arranging all the observations from lowest value to highest value and picking the middle one; (ii)If there is even number of observations, the median shall be average of the two middle values.)

Sr. No	Name of Director/KMP & Designation	Remuneration of Directors/ KMP for FY 2020-21 (Rs)	% Increase/ (Decrease) in Remuneration for the FY 2020-21	Ratio of Remuneration of each Director/KMP to the median remuneration of employee
1.	Laxmikant Ramprasad Kabra Non-Executive Director	Nil	Nil	NA
2.	Bhavesh Dhirajlal Tanna Managing Director	Nil	Nil	NA
3.	Rajkumar Govindas Baheti* Independent Director	Nil	Nil	NA
4.	Mandar Kamalakar Patil Independent Director	Nil	Nil	NA
5.	Kajal Dhanpatraj Kothari# Independent Director	Nil	Nil	NA
6.	Archana Dakhale Independent Director \$	Nil	Nil	NA
7.	Umesh Ravindranath More % Executive Director	Nil	Nil	NA
8.	Tejas Arun Deherkar Chief Financial officer	2,60,000	80.56%	21.99%
8.	Chintan Doshi Company Secretary	1,80,000	0%	15.22%

* Appointed as the Independent Director w.e.f February 10, 2021

Appointed as the Additional Independent Director of the Company on September 09, 2020

% Appointed as the Director in the Executive Category w.e.f November 12, 2020

\$ Ceased to be independent directors w.e.f September 09, 2020.

- The numbers of permanent employees on the rolls of the Company as on 31st March 2021: 6



3. Average percentage increase in the salaries of employees other than the managerial personnel in the last financial year i.e., 2020-21 was 10%, whereas increase in the managerial remuneration for the same financial year was 35.81%. Managerial remuneration paid during the financial year 2020-21 was as per the provisions of the Companies Act, 2013 and the Remuneration Policy of your Company.
4. **Affirmation that the remuneration is as per the remuneration policy of the Company:** It is hereby affirmed that the Remuneration paid to the Directors is as per the Remuneration Policy of the Company.

DETAILS OF THE REMUNERATION OF DIRECTORS, KMP'S AND EMPLOYEES

Statement pursuant to Section 197(12) of the Companies Act, 2013 read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 for the year ended on March 31, 2021

1. Details of employees employed throughout the year and in receipt of remuneration at the rate of not less than One crore two Lakh rupees per annum: **None**
2. Details of employees employed for a part of the financial year and in receipt of remuneration for any part of the year, at a rate which, in aggregate, was not less than Eight Lakh Fifty thousand rupees per month: **None**
3. Details of employees employed throughout the financial year or part thereof and was in receipt of remuneration in the year and is in excess of the remuneration of the Managing Director or Whole Time Director and manager and holds by himself or along with his spouse and dependent children, not less than two percent of the equity shares of the company: **None**

For and On Behalf of the Board of Directors
Eiko LifeSciences Limited

Laxmikant Ramprasad Kabra
Chairman
DIN: 00061346

Date: 25.08.2021

Place: Thane



FORM NO. MR-3 SECRETARIAL AUDIT REPORT

For the Financial Year ended 31st March 2021

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To
The Board of Directors
M/s. Eiko LifeSciences Limited
(Formerly Known as "M/s. Narendra Investments (Delhi) Limited")

CIN: L65993MH1977PLC258134

604, Centrum, Opp. TMC Office Near Satkar Grande Hotel,
Wagle Estate Thane 400604

Dear Members,

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. Eiko LifeSciences Limited (Formerly Known as "M/s. Narendra Investments (Delhi) Limited") (hereinafter called the "company"). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my/our opinion, the company has, during the audit period covering the financial year ended on 31st March 2021, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed, and other records maintained by Company for the financial year ended on 31st March 2021 according to the provisions of:

- a) The Companies Act 2013 and the Rules made thereunder.
- b) The Depositories Act, 1996 and the Regulations and Byelaws framed there under.
- c) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under.
- d) Foreign Exchange Management Act, 1999 and the applicable rules and regulations made there under; - Not Applicable as there was no Foreign Direct Investment, Overseas Direct Investment or External Commercial Borrowing During the Period under review
- e) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act').
 - The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
 - The Securities and Exchange Board of India (Prohibition of Insider Trading Regulations) 2015.
 - The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.
 - The Securities and Exchange Board of India (Share based Employee Benefit) Regulation, 2014: **Not Applicable during the period under Review**
 - The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
 - The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client.
 - The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009- **Not Applicable during the period under Review**



- The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 - **Not Applicable during the period under Review**

f) The other laws as are applicable specifically to the Company are compiled during the period under review.

I have also examined compliance with the applicable clauses of the following:

- i. Secretarial Standards issued by The Institute of Company Secretaries of India-
- ii. The Listing Agreement entered by the Company with BSE Ltd

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above:

I further report that, during the year under review:

The Board of Directors of the Company is duly constituted with proper balance of Executive, Non-Executive Directors, and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Companies Act, 2013.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda are sent at least seven days in advance, a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting. Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations, and guidelines.

I further report that during the Audit period the company has had the following specific events/actions having a major bearing on the company's affairs in pursuance of above referred laws, rules, regulations, guidelines, standards etc.,

and the same being in the nature of Price Sensitive Information has been intimated to the Stock Exchange:

- a. The allotment equity shares up to 24,29,967 (Twenty-Four Lakh Twenty-Nine Thousand Nine Hundred Sixty-Seven) equity shares of the Company having a face value of Rs. 10/- (Rupees Ten Only) each, at Rs. 30/- (Rupees Thirty only) (including a premium of 20 /- (Rupees Twenty only), aggregating up to Rs. 7,28,99,010/- (Rupees Seven Crores Twenty-Eight Lakhs Ninety-Nine Thousand and Ten only) ("Preferential Issue") to Investors.
- b. To change of the name of the Company from 'Narendra Investments (Delhi) Limited' To 'Eiko LifeSciences Limited'
- c. Acquisition And Purchase of The Business Of M/S Urvi Speciality Chemicals on A Slump Sale Basis

**Shravan A. Gupta & Associates
Practicing Company Secretary**

Shravan A. Gupta
ACS: 27484,
CP: 9990

UDIN: A027484C000794844

Place: Mumbai
Date: 17.08.2021



SECRETARIAL COMPLIANCE REPORT OF NARENDRA INVESTMENTS (DELHI) LIMITED FOR THE YEAR ENDED 31ST MARCH 2021

Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Secretarial Compliance report of Narendra Investments (Delhi) Limited for the year ended March 31, 2021.

I, **Shravan A. Gupta**, Company Secretary in whole time practice have examined:

- a. All the documents and records made available to me, and explanation provided by Narendra Investments (Delhi) Limited (“the listed entity”)
- b. The filings/ submissions made by the listed entity to the stock exchanges,
- c. Website of the listed entity,
- d. Any other document/ filing, as may be relevant, which has been relied upon to make this certification, for the year ended 31/03/2021 (“Review Period”) in respect of compliance with the provisions of-
 - The Securities and Exchange Board of India Act, 1992 (“SEBI Act”) and the Regulations, circulars, guidelines issued thereunder; and
 - The Securities Contracts (Regulation) Act, 1956 (“SCRA”), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India (“SEBI”);

The specific Regulations, whose provisions and the circulars/ guidelines issued and applicable thereunder, have been examined, include-

- a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
- b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018
- c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

- d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018
- e) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014
- f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008
- g) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations, 2013
- h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
- i) and other circulars/ guidelines issued and applicable to the company thereunder

Based on the above examination, I hereby report that, during the Review Period:

- a. The listed entity has complied with the applicable provisions of the above Regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below-
- b. The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder insofar as it appears from my examination of those records.
- c. The following are the details of actions taken against the listed entity/ its promoters/ directors/ material subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder:



Sr. No.	Action taken by	Details of violation	Details of action taken E.g., fines, warning letter, debarment, etc.	Observations/ remarks of the Practicing Company Secretary, if any.
1.	The Bombay Stock Exchange	Regulation 23(9) Non-Disclosures of Related Party Transaction within the period prescribed under the regulation	Fine of ₹1,71,100	Reply for Waiver of Penalty has been filed as on 06/02/21; same has been Pending to for consideration by Bombay Stock Exchange

d. The listed entity has taken the following actions to comply with the observations made in previous reports:

Observations of the Practicing Company Secretary in the previous reports	Observations made in the secretarial compliance report for the year ended.	Actions taken by the listed entity, if any	Comments of the Practicing Company Secretary on the actions taken by the listed entity
Not Applicable	Not Applicable	Not Applicable	Not Applicable

Shravan A. Gupta & Associates
Practicing Company Secretary

Shravan A. Gupta
ACS: 27484,
CP: 9990
UDIN: A027484C000183816

Place: Mumbai
Date: 26/04/2021

Note:

The Secretarial compliance report was issued by secretarial auditor on April 26, 2021, i.e., before change in name of the Company. The name of the Company has changed from **Narendra Investments (Delhi) Limited** to **Eiko LifeSciences Limited** with effect from **June 24, 2021**, i.e., post review period. Therefore, former name i.e., **Narendra Investments (Delhi) Limited** is reflecting in the Secretarial compliance report.



CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Sub-clause 10(i) of Para – C of Schedule – V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The members of
Eiko LifeSciences Limited
(Formerly Known as “Narendra Investments (Delhi) Limited”)

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Eiko LifeSciences Limited** having CIN: L65993MH1977PLC258134 and having registered office at 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate Thane MH 400604, Maharashtra, (hereinafter referred to as ‘the Company’), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Sub-clause 10(i) of Para – C of Schedule – V of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal (www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers. I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ended on 31st March 2021, have been debarred or disqualified from being appointed or continuing as Directors of Companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority

Sr. No.	Names of Director	DIN	Date of Appointment in Company
1.	Mr. Laxmikant Ramprasad Kabra	00061346	26/08/2013
2.	Mr. Bhavesh Dhirajlal Tanna	03353445	26/08/2013
3.	Mr. Rajkumar Govindas Baheti	05164182	10/02/2021
4.	Mr. Mandar Kamalakar Patil	05284076	17/10/2014
5.	Ms. Kajal Dhanpatraj Kothari	07058562	09/09/2020
6.	Mr. Umesh Ravindranath More	09044162	12/11/2020

Ensuring the eligibility for the appointment or continuity of every director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Shravan A. Gupta & Associates
Company Secretaries

Shravan A Gupta
Proprietor
ACS No. 27484; COP No. 9990
UDIN: A027484C000797770

Date: 17.08.2021
Place: Mumbai



REPORT ON CORPORATE GOVERNANCE

The Company is in compliance with the requirements stipulated under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) with regard to corporate governance.

1. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE

The Company's philosophy on corporate governance envisages the attainment of the highest level of transparency, accountability, and equity, in all facets of its operations, and in all its interactions with its stakeholders, including shareholders, employees, the government and lenders.

2. BOARD OF DIRECTORS

a. Size and composition of the Board:

The Board of Directors ('the Board') of your Company comprises of the optimum combination of Executive and Non – Executive Directors to maintain the independence of the Board and separate its functions of governance and management. The Board is at the core of your Company's corporate governance practice and oversees how the Management serves and protects the long-term interests of all stakeholders.

Composition: The Board, as on March 31, 2021, consists of 6 directors, comprising of 4 Non-Executive Directors, and 2 Executive Director. The composition of the Board of Directors is given below:

Name of Director	Category of Director	No. of Director-ships held	Committee Member/ Chairman of Board Committees in other companies		Relation ship with another Director	No. of ordinary shares held as on 31 st March 2021
			Chairman	Members		
Laxmikant Ramprasad Kabra	Chairman Non-Executive, Promoter Director	1	1	2	N.A.	20,000
Bhavesh Dhirajlal Tanna	Managing Director Promoter Director	Nil	Nil	Nil	N.A.	2,02,000
Rajkumar Govindas Baheti	Non-Executive, Independent Director	Nil	Nil	Nil	N.A.	-
Mandar Kamalakar Patil	Non-Executive, Independent Director	Nil	Nil	Nil	N.A.	-
Kajal Dhanpatraj Kothari	Non-Executive, Independent Director	Nil	Nil	Nil	N.A.	-
Umesh Ravindranath More	Executive Non-Promoter	Nil	Nil	Nil	N.A.	-

Details of directors seeking reappointment pursuant to regulation 36(3) of Sebi (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Secretarial Standard-2 on General Meetings has been given as "Annexure A" of the Notice of the Annual General Meeting.

Note:

- Directorship held by directors as mentioned above, excludes directorship in Narendra Investments (Delhi) Limited and excludes directorships in Private limited Companies, Foreign Companies and Companies under Section 8 of the Companies Act, 2013.



- Committees considered are Audit Committee and Stakeholders Relationship Committee and excludes committees of Narendra Investments (Delhi) Limited.

b. Board Meetings and Attendance:

Six Board Meetings were held during the period from April 1, 2020, to March 31, 2021, on the following dates: June 27, 2020, September 08, 2020, October 3, 2020, November 12, 2020, February 10, 2021, and March 01, 2021. The Director’s attendance at the Board Meetings during the period and at the last Annual General Meeting is given below:

Detail of Directors attended the last Annual General Meeting held on 30th September 2020 are given below:

Name of Director	No. of Board Meetings Attended	Attendance at last AGM
Laxmikant Ramprasad Kabra	6	Yes
Bhavesh Dhirajlal Tanna	6	Yes
Rajkumar Govindas Baheti	1	No
Mandar Kamalakar Patil	6	Yes
Kajal Dhanpatraj Kothari	2	No
Umesh Ravindranath More	2	No

3. COMMITTEES OF THE BOARD

Currently the Boards have three committees viz:

a. Audit Committee:

Composition:

The Audit Committee has been constituted in conformity with the requirements of Section – 177 of the Companies Act, 2013. The Audit Committee was last reconstituted by the Board of Directors at its meeting held on November 12, 2020, pursuant to resignation of Ms. Archana Dakhale, Independent/ Non-Executive Director. The members of the Committee are Mr. Mandar Kamalkar Patil (Chairman), Mr. Bhavesh Dhirajlal Tanna (Member), and Ms. Kajal Dhanpatraj Kothari (Member), Mr. Chintan Bharatbhai Doshi, Company Secretary, is the Secretary to the Committee. The Committee held six meetings during the year 2020-2021.

At present the Audit Committee comprises of 1 non-independent director and 2 Independent Directors All the members are financially literate and have adequate accounting knowledge. The Audit Committee met four times during the financial year.

Details of the composition, number of meetings held during the year and attendance thereat are as under:

Sr. No.	Name of the Director	Designation	Meetings Attended	Category
1	Mandar Patil	Chairman	6	Non-Executive Independent Director
2	Kajal Kothari	Member	2	Non-Executive Independent Director
3	Bhavesh Tanna	Member	6	Executive Non-Independent Director

Minutes of meetings of the Audit Committee are circulated to members of the Committee and the Board is kept apprised. Members of the Audit Committee have requisite financial and management expertise. The Statutory Auditors are invited to attend and participate at meetings of the Committee.



The Scope of the Audit Committee includes:

- a) Overview of the company's financial reporting process and the disclosure of its financial Information to ensure that the financial statement is correct, sufficient, and credible.
- b) Recommending the appointment and removal of external auditor, fixation of audit fee and also approval for payment for any other services.
- c) Reviewing with management the annual financial statements before submission to the Board, focusing primarily on matters required to be included in the Director's Responsibilities Statement to be include in the board report in terms of clause (c) of sub-Section 3 of Section 134 of the Companies Act, 2013
 - Any changes in accounting policies and practices
 - Major accounting entries based on exercise of judgment by management.
 - Qualifications in draft audit report.
 - Significant adjustments arising out of audit.
 - The going concern assumption.
 - Compliance with accounting standards.
 - Compliance with stock exchange and legal requirements concerning financial statements.
 - Any related party transactions i.e., transactions of the Company of material nature, with promoters or the management, their subsidiaries, or relatives etc. that may have potential conflict with interests of Company at large.
- d) Reviewing with management, external and internal auditors, the adequacy of internal control systems.
- e) Reviewing the periodical financial statements with management before submission to the board for their approval.
- f) Reviewing the adequacy of internal audit function, the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit.
- g) Discussion with internal auditors any significant findings and follow up there on.
- h) Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board.
- i) Discussions with external auditors before the audit commence nature and scope of audit as well as have post-audit discussion to ascertain any area of concern.
- j) Reviewing the Company's financial and risk management policies.
- k) To investigate the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors

b. Stakeholders' Relationship Committee

The Stakeholder's Relationship / shareholders Committee (SRC) is formed in accordance with Section 178 of the Companies Act, 2013. The Committee was last reconstituted by the Board of Directors at its meeting held on November 12, 2020, pursuant to resignation of Ms. Archana Dakhale, Independent/ Non-Executive Director. The members of the



Committee are Mr. Mandar Patil (Chairman) and Kajal Dhanpatraj Kothari, Mr. Chintan Bharatbhai Doshi, Company Secretary, is designated Compliance Officer and the Secretary to the Committee. The Committee held Four meetings during the year 2020-2021. The attendance of members was as under:

Sr. No.	Name of the Director	Designation	Meetings Attended	Category
1.	Mandar Patil	Chairman	4	Non-Executive Independent Director
2.	Kajal Kothari	Member	2	Non-Executive Independent Director

This committee investigates redressal of shareholder complaints regarding transfer of shares, non-receipt of Balance Sheet and non-receipt of declared dividends, as well as those required under Act and the Listing Regulations.

Following is a summary of complaints received and disposed of during the year:

1.	No. of complaints received	Nil
2.	No. of complaints disposed	Nil
3.	No. of complaints pending	Nil

The scope of the Stakeholders' Relationship Committee includes:

- a) To oversee and review all matters connected with transfer of Company's securities.
- b) To approve issue of duplicate of shares / debentures certificates.
- c) To oversee the performance of the Company's Share Transfer Agent.
- d) To resolve the grievances of the security holders of the Company including complaints related to transfer/ transmission of shares, non-receipt of Annual Report, non-receipt of declared dividends, issue of new / duplicate certificates, General Meetings etc.
- e) To investigate into complaints relating to allotment of shares, approval of transfers or transmission of shares, debentures, or any other securities.
- f) To review the measures taken for effective exercise of voting rights by Shareholders.
- g) To review adherence to the service standards adopted by the Company in respect of various services being rendered by the Share Transfer Agent and recommend methods to upgrade the service standards adopted by the Company.
- h) To review various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the security holders of the Company.
- i) To carry out any other function as is mandated by the Board of Directors from time to time and / or enforced by any statutory notification(s), amendment(s) or modification(s) as may be applicable.
- j) To specifically investigate various aspects of interest of Shareholders, debenture-holders, and other security holders.



c. Nomination & Remuneration Committee:

The Committee was last reconstituted by the Board of Directors at its meeting held on November 12, 2020, pursuant to resignation of Ms. Archana Dakhale, Independent/ Non-Executive Director. The Members of the Committee are Mr. Mandar Kamalkar Patil (Chairman), Ms. Kajal Dhanpatraj Kothari and Mr. Laxmikant Ramprasad Kabra, Mr. Chintan Bharatbhai Doshi, Company Secretary, is the Secretary to the Committee.

During FY 2020-21, four Meetings of the Nomination and Remuneration Committee were held on 08th September 2020, 12th November 2020, 10th February 2021 and 01st March 2021 respectively. The composition of the Nomination and Remuneration Committee and the attendance of the Members at its Meetings held during FY 2020-21, are given below:

Sr. No.	Name of the Director	Designation	Meetings Attended	Category
1.	Mandar Patil	Chairman	4	Non-Executive Independent Director
2.	Ms. Kajal Kothari	Member	2	Non-Executive Independent Director
3.	Mr. Laxmikant Kabra	Member	2	Non-Executive Director

The terms of reference of the Nomination and Remuneration Committee are in accordance with the Companies Act, 2013 (as amended by Companies (Amendment) Act, 2017), which inter-alia, include the following:

- Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board of Directors a policy, relating to the remuneration for the directors, key managerial personnel, and other employees.
- To identify persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, recommended to the Board their appointment and removal if necessary, and shall specify the manner for effective evaluation of performance of Board, its committees and individual directors to be carried out either by the Board, by the Nomination and Remuneration Committee or by an independent external agency and review its implementation and compliance.
- Formulation of criteria for evaluation of performance of independent directors and the board of directors.
- Devising a policy on diversity of Board of Directors.
- Recommend to the board, all remuneration, in whatever form, payable to senior management.

4. CODE OF CONDUCT FOR SENIOR MANAGEMENT

The Company has adopted a Code of Conduct for Directors and Senior Management. The Code includes provisions where the employees of the Company can voice their concerns on violation and potential violation of this Code in a responsible and effective manner.

All Board members and senior management personnel have confirmed compliance with the code. A declaration signed by the Managing Director is attached and forms part of the Annual Report of the company.

5. GENERAL BODY MEETINGS

Location and time of Annual General Meetings held in last three years

FOR THE YEAR	LOCATION	DATE & TIME	SPECIAL RESOLUTION PASSED
2019-20	Through Video Conference – (Deemed Venue: 1, Matru Chhaya, Maharshi Karve Road, Opp. Dr. Bedekar Hospital, Naupada, Thane (West) Maharashtra – 400 602)	30 th September 2020, 4.00 P.M.	No
2018-19	1, Matru Chhaya, Maharshi Karve Road, Opp. Dr. Bedekar Hospital, Naupada, Thane (West) Maharashtra – 400 602	30 th September 2019, 04:00 PM	No
2017-18	1, Matru Chhaya, Maharshi Karve Road, Opp. Dr. Bedekar Hospital, Naupada, Thane (West) Maharashtra – 400 602	29 th September 2018, 04:00 PM	Yes

6. MEANS OF COMMUNICATION

1.	Quarterly Results	The unaudited quarterly results and audited results for the year are published in one English newspaper and at least one vernacular newspaper and in official website of Bombay Stock Exchange (www.bseindia.com) and on Company website.
2.	Publication in News Papers	Published in one English newspaper and at least one vernacular newspaper
3.	Publications in Websites	www.narendrainvestment.com , www.bseindia.com
4.	Displaying of official news releases	www.narendrainvestment.com , www.bseindia.com
5.	Presentations made to institutional investors or to the analysts.	Not applicable.

7. SHAREHOLDERS INFORMATION

A. Annual General Meeting:

Date	:	28 th September 2021
Time	:	04:30 PM, Tuesday
Registered Office	:	604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate Thane 400604
Venue	:	Through Video Conferencing (VC)/Other Audio-Visual Means (OAVM)

B. Financial Calendar (Tentative):

The financial year covers the period from 1st April to 31st March.

Calendar for the Board Meetings to be held to review / approve the financial results of the company for FY 2021-22 is given below:

Financial reporting for the quarter ending June 30,2021	4 th week of July, 2021
Financial reporting for the half year ending September 30,2021	1 st Week of November, 2021
Financial reporting for the quarter ending December 31,2021	1 st Week of February, 2022
Financial reporting for the year ending March 31, 2022	Last week of May, 2022
Annual General Meeting for the year ending March 31,2021	Last week of September, 2022



C. Book Closure Date:

Wednesday, 22nd September 2021 to Tuesday, 28th September 2021 (both days inclusive)

D. Listing on stock exchange:

BSE Limited (BSE)

Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001

Listing fees for F.Y. 2020-21 of BSE has been paid

E. Stock code:

BSE Limited (BSE): 540204

F. Stock price data:

The company's shares are listed at BSE Ltd. Accordingly, monthly High-Low Quotation of shares traded at BSE Ltd. as are as under:

Period	High (₹)	Low (₹)
April 2020	9.95	7.66
May 2020	11.23	8.54
June 2020	17.30	11.79
July 2020	22.50	18.15
August 2020	32.75	23.60
September 2020	40.55	32.65
October 2020	34.15	27.55
November 2020	30.35	25.65
December 2020	34.00	30.00
January 2021	36.00	34.00
February 2021	47.15	36.00
March 2021	79.85	39.65

G. Categories of Shareholders as on 31st March 2021

Sr. No.	Category	No. of Shares	% of Shares
A	Promoter's Holding		
1	Indian Promoters	8,16,414	21.37
2	Foreign Promoters	-	-
	Sub total	8,16,414	21.37
B	Non-Promoters		
3	Institutional Investors	--	--
	A. Mutual Funds and UTI	--	--
	B. Banks, Financial Institutions., Insurance Companies	--	--
	Subtotal	--	--



4	Non-Institutional Investors		
	A. Bodies Corporate	7,15,001	18.72
	B. Individuals/HUF	22,88,494	59.91
	C. NRIs/Clearing Member/OCBs	--	--
	Sub total	30,03,586	78.63
	GRAND TOTAL	38,20,000	100

H. Distribution of Shareholding as on March 31, 2021

No. of Equity shares held	No of shareholders	% of shareholders	No of shares held	% of holding
1-500	177	57.65	24,894	0.65
501-1000	27	8.79	22,132	0.58
1001-2000	15	4.89	24,146	0.63
2001-3000	16	5.22	42,721	1.12
3001-4000	9	2.93	31,436	0.82
4001-5000	9	2.93	41,922	1.09
5001-10000	6	1.95	39,068	1.03
10001 & above	48	15.64	35,93,681	94.08
Total	307	100	38,20,000	100

I. Dematerialization of shares:

The trading in Equity Shares of the company is permitted only in dematerialized form. The company has joined on National Securities Depository Ltd. (NSDL) and Central Depository Services (India) Ltd. (CDSL). As on 31st March 2021 **99.68%** of the Company's shares are in dematerialized mode.

ISIN: INE666Q01016

J. Outstanding GDR'S/ ADR'S/ Warrants/ Convertible Instruments: Not applicable

K. Address for Correspondence:

Register and Share Transfer Agent
M/s. Bigshare Services Pvt. Ltd.
1st Floor, Bharat Tin Works Building,
Opp. Vasant Oasis, Makwana Road,
Marol, Andheri (East), Mumbai, Maharashtra-400059

Company Secretary & Compliance Officer

Mr. Avi Mundecha
Email: investor.relations@eikolifesciences.com

L. Website: www.narendrainvestment.com



M. Disclosures:

1. There are no materially significant related party transactions of the Company with key managerial personnel which have potential conflict with the interest of the Company at large.
2. Details of non – compliance by the Company, penalties and strictures imposed on the Company by Stock Exchanges or SEBI or any statutory authority, on any matter related to capital markets, during the period from 1st April 2020 to 31st March, 2021:

Action taken by	Details of Violation	Details of action taken Example, Fines, Penalty, warning letter, etc.	Observation/ Remarks of practicing company secretary if any
The BSE	Regulation 23(9) Non-compliance with disclosure of related party transactions on consolidated basis.	Fine of ₹1,45,000/-	Reply for waiver of fine has been sent to BSE on January 19, 2021. Further reply sent on February 06, 2021, to email received from BSE email dated February 05, 2021. The same is waived by BSE vide email dated July 20, 2021.
The BSE	Regulation 33 Non-Submission of the financial results within the period prescribed under this regulation	Fine of ₹88,500/-	Reply for waiver of fine has been sent to BSE on 11/09/2019. The same is pending for consideration.

3. The Company has established vigil mechanism, whistle blower policy, and no personnel has been denied access to the audit committee.
4. The Company has also complied with and adopted the mandatory requirements of SEBI (LODR) Regulations, 2015, Companies Act, 2013 and applicable Secretarial Standards.
5. Board of Directors of the Company confirm that in their opinion the independent directors fulfill the conditions specified in the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and are independent of the management.
6. Policy on related party transaction and all other Policies/Disclosures required under Companies Act, 2013 / SEBI LODR Regulations, 2015 are available on the weblink: www.narendrainvestment.com
7. As required by Regulation 17(8) of the SEBI Listing Regulations, the Managing Director and the Chief Financial Officer have submitted a Certificate to the Board of Directors in the prescribed format for the financial year ended March 31, 2021, confirming the correctness of the financial statements and cashflow statement, and adequacy of the internal control measures and reporting of matters to the Audit Committee, which is annexed.
8. Company has raised part funds through initiating the process of preferential allotment; however, the said fund was not utilized till 31st March 2021 as process for preferential allotment was not completed till March 2021. Therefore, details of utilization of such funds are not disclosed or applicable.



9. Pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Shraavan A. Gupta & Associates, Company Secretaries, issued a certificate dated August 17, 2021 (annexed to Secretarial Audit Report) certifying that none of the directors on the board of the Company have been debarred or disqualified from being appointed or continuing as directors of companies by SEBI or Ministry of Corporate Affairs or any such statutory authority.
10. As Corporate Governance provision are not applicable to the Company, therefore Company is not required to attached auditors' certificate on compliance with the conditions of Corporate Governance under SEBI Listing Regulations
11. During the financial year ended March 31, 2021, all recommendations of the Committees of the Board of Directors, which are mandatorily required, have been accepted by the Board of Directors of your Company.
12. Details of fees paid by your Company during financial year 2020-2021 on a consolidated basis to the statutory auditor and all entities in the network firm/network entity of which the statutory auditor is a part:
Statutory Audit Fees: ₹30,000
13. Disclosures in relation to the Sexual Harassment of Women at the Workplace (Prevention, Prohibition and Redressal) Act, 2013:
 - Number of complaints filed during the financial year - NIL
 - Number of complaints disposed of during the financial year - NIL
 - Number of complaints pending as on end of the financial year - NIL
14. Non-Mandatory Requirements' Disclosure Under Sebi Listing Regulations

CHAIRMAN OF THE BOARD:

Whether Chairman of the Board is entitled to maintain a Chairman's Office at the Company's expense and allowed reimbursement of expenses incurred in performance of his duties: **No**

MODIFIED OPINION IN AUDIT REPORT:

The Auditors have issued an unmodified opinion for the year ended March 31, 2021.

SEPARATE POSTS OF CHAIRMAN AND MANAGING DIRECTOR:

Separate persons perform the role of Chairman and Managing Director.

REPORTING OF INTERNAL AUDITOR:

The internal auditor reports directly to the Audit Committee and quarterly internal audit reports are reviewed in the Audit Committee meetings

For and On Behalf of the Board of Directors
Eiko LifeSciences Limited

Laxmikant Ramprasad Kabra
Chairman
DIN: 00061346

Date: 25.08.2021
Place: Thane



DECLARATION REGARDING AFFIRMATION OF CODE OF CONDUCT

In accordance with Regulation 26(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board Members, and Senior Management personnel of the Company have confirmed compliance with the Code of Business Conduct and Ethics for the financial year ended March 31, 2021.

For and on behalf of the Board of Directors

Eiko LifeSciences Limited

Laxmikant Ramprasad Kabra

Chairman

DIN: 09044162

Date: 20.04.2021

Place: Thane

DECLARATION BY THE MD AND CFO – PURSUANT TO REGULATION 17(8) OF SEBI LISTING REGULATIONS

We have reviewed financial statements and the Cash Flow Statement for the year ended March 31, 2021, and certify, to the best of our knowledge and belief, that:

- A. We have reviewed financial statements and the cash flow statement for the year and that to the best of our knowledge and belief:
1. these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
 2. these statements together present a true and fair view of the listed entity's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. There are, to the best of our knowledge and belief, no transactions entered into by the listed entity during the year which are fraudulent, illegal or violative of the Company's code of conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and that they have evaluated the effectiveness of internal control systems of the listed entity pertaining to financial reporting and they have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of

which they are aware and the steps they have taken or propose to take to rectify these deficiencies.

- D. We have indicated to the auditors and the Audit committee –
1. significant changes in internal control over financial reporting during the year.
 2. significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 3. instances of significant fraud of which they have become aware and the involvement therein, if any, of the management or an employee having a significant role in the listed entity's internal control system over financial reporting.

For and on behalf of the Board of Directors

Eiko LifeSciences Limited

Bhavesh Tanna

Managing director

Din: 033534452

Tejas Arun Deherkar

Chief Financial Officer

Date: 20.04.2021

Place: Thane



MANAGEMENT DISCUSSION AND ANALYSIS REPORT

INDUSTRY STRUCTURE

- The Company is a manufacturer of specialty and fine chemicals. Company's Specialty Chemicals product offerings comprise of Organic as well as and Inorganic chemicals.
- Specialty and fine chemicals are knowledge chemicals which require specialized skills and knowledge for manufacture in terms of chemistry and engineering capabilities, material handling and effluent treatment.
- Specialty and fine chemicals are required in several end use applications ranging from Lifesciences (Agrochemical and Pharmaceuticals) to Electronic Chemicals. Production of specialty chemicals requires good knowledge of the requirements of the end user applications to whose needs they are meant to cater.
- All specialty and fine chemicals are subject to varying degrees of regulatory requirements and the demand for these chemicals can be impacted by changes in regulations.
- Given the specialized knowledge component involved, there are limited number of producers in India for the range of products manufactured by the Company.

OPPORTUNITY & SECTOR-WISE OUTLOOK

The factors driving the growth of the specialty chemicals market include large base of end-use industries, high demand from Asia Pacific, increasing demand from automotive industry, and technological advancements. Over and above, faster end-use industry growth, low penetration of specialty chemicals in India will support growth.

Your Company is engaged in manufacturing of specialty chemicals and intermediates following major segments:

1. Pharmaceuticals
2. Performance chemicals for industrial application
3. Material sciences

SEGMENT

The primary segment that your Company operates in is field of Specialty and fine Chemical, and their related products.

During the year under review, income from operations stood at ₹11,99,05,799/- and Profit after tax stood at ₹61,43,294/-.

MATERIAL DEVELOPMENT IN HUMAN RESOURCES AND INDUSTRIAL RELATION FRONT

The Company is maintaining good relations with its employees and currently employs about Six employees in all categories. The Company values and understands the need for continuous growth and development of its people to have greater productivity and provide job satisfaction and also equip them to meet growing organizational challenges. Your Company has genuine concern and top priority for safety and welfare of its employees.

INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY

The Company has proper and adequate system of internal audit and controls which ensure that all the assets are safeguarded against loss from unauthorized use or disposition and that all transactions are authorized, recorded, and reported correctly.

The Company continuously strives to improve upon/evolve and implement best practices with a view to strengthen the internal control systems.

The Company has assigned internal audit function to a leading firm of Chartered Accountants. Regular internal audit and checks are carried out to ensure that the responsibilities are discharged effectively. All major findings and suggestions arising out of internal audit are reported and reviewed by the Audit Committee. The Management ensures implementation of these suggestions and reviews them periodically.

RESEARCH AND DEVELOPMENT

Research and Development (R&D) plays a pivotal role in innovation and invention of new molecules. New product development is always a priority for the Company as needs of consumers is constantly changing globally. Apart from new product development, it's paramount for specialty



chemicals company to develop and upgrade existing products. Investment on research and development (R&D) is never wasted as the right kind of product and breakthrough can help the company to have an edge over competitors. Your Company emboldens R&D to cater to the need of our customers, and we have developed a number of niche molecules chemicals as per customer specifications for pharmaceutical industries, Agro Chemicals, fragrance and flavors.

ENVIRONMENTAL ISSUES

The Company is constantly engaged in upgrading our manufacturing processes by adopting to best available technology, which is environmentally sustainable and safe to operate. The primary focus of the Company has been pollution control and clean environment solution. Our aim is to have processes that have 'zero' impact on employees and the environment. We follow efficient manufacturing processes by using minimum energy and raw materials. The effluents generated at our manufacturing units are treated on-site to meet all the standards set by regulatory authorities.

FINANCIAL PERFORMANCE WITH RESPECT TO OPERATION PERFORMANCE

The Company has all the plans for tight budgetary control on key operational performance indication with judicious deployment of funds without resorting to any kind of borrowing wherever possible.

CAUTIONARY STATEMENT

Statement in this report on Management Discussion and Analysis may be forward looking statement within the meaning of applicable security laws or regulations. These statements are based on certain assumptions and expectations of future events. Actual results could, however, differ materially from those expressed or implied.

Important factors that could make a difference to the company's operations include global and domestic demand supply conditions, finished goods prices, raw material cost and availability and changes in government regulations and tax structure, economic development within India and the countries with which the company has business contacts and other factors such as litigation and industrial relations.

The Company assumes no responsibility in respect of forward – looking statements, which may be amended or modified in future on the basis of subsequent developments, information or events.

**For and On Behalf of the Board of Directors
Eiko LifeSciences Limited**

Laxmikant Ramprasad Kabra

Chairman

DIN: 00061346

Date: 25.08.2021

Place: Thane



INDEPENDENT AUDITOR'S REPORT

To,
The Members
Eiko LifeSciences Limited
(Formerly known as Narendra Investment (Delhi) Limited)

Opinion

We have audited the financial statements of EIKO LIFESCIENCES LIMITED ("the Company"), which comprise the balance sheet as of 31st March 2021, and the statement of profit and loss (including other comprehensive income), statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March 2021, and profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key Audit Matter: -	How the matter was addressed in our Audit: -
1) Revenue Recognition Revenue from sale of goods is recognised when the control of the goods has passed, which is usually on delivery of the goods. There is a risk of revenue being overstated on account of it being recorded in the wrong period.	In view of the importance of the matter we applied the following audit procedures in this area, among others to obtain sufficient audit evidence: <ul style="list-style-type: none">▪ We have evaluated the process followed by the company for revenue recognition including understanding and testing of key controls relating to recognition of revenue in correct period.▪ We have inspected documentation/records for sales transactions recorded both side of year-end to determine if revenue has been recognised in the correct period; and▪ We have critically assessed manual journals posted to revenue to identify unusual or irregular items.



2) Valuation of Inventories

Inventories held by company comprising Work in progress or Raw Material may be held for long periods of time before sale making it vulnerable to reduction in net realizable value (NRV). This could result in an overstatement of the value of inventory when the carrying value is higher than the NRV.

For NRV assessment, the estimated selling price is determined for a phase, sometimes comprising multiple units. The assessment and application of write-down of inventory to NRV are subject to significant judgements. As such inappropriate assumptions in these judgements can impact the assessment of the carrying value of inventories. Considering the management's judgement associated with long dated estimation of future market and economic conditions, we have considered assessment of net realizable value of inventory as a key audit matter.

Our audit procedures to assess the net realizable value (NRV) of inventories included the following:

- Understanding the basis of estimated selling price for the unsold units and work in progress.
- Evaluating the design and testing operating effectiveness of controls over preparation and update of NRV workings by designated personnel. Testing controls related to review of key estimates, including estimated future selling prices and costs of completion for property development projects.
- Evaluating the management's judgement with regards to application of write-down of inventory units by auditing the key estimates, data inputs and assumptions adopted in the valuations. Comparing expected future average selling prices with available market conditions such as price range available under industry reports published by reputed consultants.

Other Information

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report but does not include the Financial Statements and our auditors' report thereon.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibilities for the Financial Results

These Financial Results have been prepared on the basis of the annual Financial Statements. The Company's Board of Directors are responsible for the preparation and presentation of these Financial Results that give a true and

fair view of the net profit and other comprehensive income and other financial information of the Company and the balance sheet and the statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Financial Results by the Directors of the Company, as aforesaid.



In preparing the Financial Results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results


Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- i. Identify and assess the risks of material misstatement of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ii. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to Financial Statements in place and the operating effectiveness of such controls.
- iii. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- iv. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- v. Evaluate the overall presentation, structure and content of the Financial Results including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- vi. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2016 ('the Order') issued by the Central Government of



India in terms of Section 143(11) of the Act, we give in the “Annexure 1” a statement on the matters specified in paragraphs 3 and 4 of the Order.

1. As required by Section 143(3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
 - b) In our opinion, proper books of accounts as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss including other comprehensive income, the statement of change in equity and the Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account.
 - d) In our opinion, the aforesaid Financial Statements comply with Ind AS specified under Section 133 of the Act.
 - e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021, from being appointed as a director in terms of Section 164(2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in “Annexure 2” to this report.
 - g) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has no pending litigations on its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company
2. With respect to the other matters to be included in the Auditor’s Report in accordance with the requirements of section 197(16) of the Act.
3. In our opinion and to the best of our information and according to the explanation given to us, the remuneration paid / provided by the company to its directors during the year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any directors is not in excess of the limit laid down U/s 197 of the IT Act. The Ministry of Corporate Affairs has not prescribed other details U/s 197 (16) which requires to be commented by us.

For Thanawala & Company
Chartered Accountants
Firm Reg. No.: 110948W

CA Vijay Thanawala
Proprietor
Membership No.: 015632

Place: Mumbai
Date: 20th April 2021

UDIN: 21015632AAAACR8007



ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT

The annexure referred to in independent auditor's report to the members of the Company on the Financial Statements for the year ended 31st March 2021. We report that:

1.
 - a. The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - b. As explained to us, the Company has a program for physical verification of fixed assets at periodic intervals. In our opinion, the period of verification is reasonable having regard to the size of the Company and the nature of its assets. The discrepancies reported on such verification were not material and have been properly dealt with in the books of account.
 - c. The company does not own any immovable properties.
2. The management has conducted physical verification of inventory at reasonable intervals during the year ended and no material discrepancies were noticed on such physical verification.
3. The Company has not granted any loans persons covered in the register maintained under section 189 of the Companies Act, 2013.
4. In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Act, with respect to the loans and investments made, as applicable.
5. The Company has not accepted any deposits from the public.
6. The Central Government of India has not prescribed maintenance of cost records under sub-section (1) of Section 148 of the Companies Act, 2013 for any of the product of the company.
7.
 - a. According to the information and explanations given to us and the records of the Company examined us by us, in our opinion, the Company is generally regular in depositing undisputed statutory dues in the respect of provident fund, employees' state insurance and service tax and is regular in depositing undisputed statutory dues in respect of investor education and protection fund, sales tax, income tax, wealth tax, customs duty, excise duty and other material statutory dues, as applicable with the appropriate authorities.
 - b. According to the information and explanation given to us and records examined by us, there are no disputed dues of GST, Sales Tax, Wealth Tax, Service Tax, Custom Duty, Excise Duty and Cess outstanding as on 31st March 2021:
8. Based on our audit procedures performed for the purpose of reporting the true and fair view of the Financial Statements and according to information and explanations given by the management, we are of the opinion that the Company has not defaulted in repayment of dues to a financial institution, bank or debenture holders or government.
9. Based on our audit procedures performed for the purpose of reporting the true and fair view of the Financial Statements and according to the information and explanations given by the management and on an overall examination of the balance sheet, we report that monies raised by way of term loans were applied for the purposes for which those were raised.
10. Based upon the audit procedures performed for the purpose of reporting the true and fair view of the Financial Statements and according to the information and explanations given by the management, we report that no fraud on or by the officers and employees of the Company has been noticed or reported during the year.
11. Based upon the audit procedures performed and the information and explanation given by the management, no managerial remuneration has been paid or provided.
12. In our opinion, the Company is not a nidhi company. Therefore, the provisions of clause 3(xi) of the order are not applicable to the Company and hence not commented upon.
13. Based on our audit procedures performed for the purpose of reporting the true and fair view of the Financial Statements and according to the information



and explanations given by the management, transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the Financial Statements, as required by the applicable accounting standards.

14. Based on our audit procedures performed for the purpose of reporting the true and fair view of the Financial Statements and according to the information and explanations given by the management, the Company has complied with provisions of section 42 of the Companies Act, 2013 in respect of the preferential allotment during the year. Based on our audit procedures performed for the purpose of reporting the true and fair view of the Financial Statements and according to the information and explanations given by the management, we report that the amounts raised, have been used for the purposes for which the funds were raised.

15. Based on our audit procedures performed for the purpose of reporting the true and fair view of the Financial Statements and according to the information and explanations given by the management, the Company has not entered into any non-cash transactions with directors or persons connected with him.

16. According to the information and explanations given to us, the provisions of section 45-IA of the Reserve Bank of India Act, 1934 are not applicable to the Company.

For Thanawala & Company

Chartered Accountants

Firm Reg. No.: 110948W

CA Vijay Thanawala

Proprietor

Membership No.: 015632

Place: Mumbai

Date: 20th April 2021

UDIN: 21015632AAAAACR8007



ANNEXURE B

TO THE INDEPENDENT AUDITORS REPORT

ANNEXURE TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE FINANCIAL STATEMENTS OF EIKO LIFESCIENCES LIMITED – 31ST MARCH 2021

Report on the internal financial controls under clause (i) of sub-section 3 of section 143 of the Act

We have audited the internal financial controls over financial reporting **EIKO LIFESCIENCES LIMITED** ('the Company') as of 31st March 2021 in conjunction with our audit of the Financial Statements of the Company for the year ended on that date.

Management's responsibility for internal financial controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the 'Guidance Note') and the Standards on Auditing deemed to be prescribed under section 143(10) of the Act to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was

established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of internal financial controls over financial reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Financial Statements for external purposes in accordance with generally accepted accounting principles.

A company's internal financial control over financial reporting includes those policies and procedures that:

1. Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company.
2. Provide reasonable assurance that transactions are recorded as necessary to permit preparation of Financial Statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company.



3. Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the Financial Statements.

Inherent limitations of internal financial controls over financial reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Thanawala & Company

Chartered Accountants

Firm Reg. No.: 110948W

CA Vijay Thanawala

Proprietor

Membership No.: 015632

Place: Mumbai

Date: 20th April 2021

UDIN: 21015632AAAACR8007



BALANCE SHEET

AS OF 31ST MARCH 2021

(Amount in ₹)

Particulars	Note No.	As at 31-03-2021	As at 31-03-2020
ASSETS			
Non-current assets			
Property, Plant and Equipment	3	24,74,853	30,91,137
Financial Assets			
Investments	4	21,94,750	50,20,300
Loans	5	3,61,15,262	3,34,65,612
Other Financial Assets	6	1,80,97,700	1,45,30,962
Deferred Tax Asset	16	2,36,517	5,11,185
		5,91,19,082	5,66,19,196
Current assets			
Inventories	7	6,35,037	
Financial Assets			
Trade Receivables	8	3,41,47,344	-
Cash and cash equivalents	9	4,07,20,171	1,76,454
Other Current Financial Assets	10	3,15,18,750	7,75,127
Other Current Assets	11	-	51,483
		10,70,21,302	10,03,064
TOTAL ASSET		16,61,40,384	5,76,22,260
EQUITY AND LIABILITIES			
EQUITY			
Equity Share capital	12	3,82,00,000	3,82,00,000
Other Equity	13	2,36,61,509	1,66,20,643
Share Application Money Pending for Allotment	14	6,33,99,600	-
		12,52,61,109	5,48,20,643
LIABILITIES			
Non-current liabilities			
Financial Liabilities			
Non-Current Borrowings	15	1,75,86,674	19,59,475
		1,75,86,674	19,59,475
Current liabilities			
Financial Liabilities			
Trade payables	17	1,89,50,252	2,951
Other financial liabilities	18	8,52,773	6,19,196
Current Tax Liabilities	19	4,90,415	93,994
Provisions	20	29,99,162	1,26,000
		2,32,92,602	8,42,141
TOTAL LIABILITIES		16,61,40,384	5,76,22,260

For Thanawala & Company

Chartered Accountants

Firm Registration No.:

CA Vijay Thanawala

Partner

Membership No.: 015632

Place: Mumbai

Date: 20th April 2021

For and Behalf of Board of Director

Laxmikant Kabra

Chairman

DIN: 00061346

Chintan Doshi

Company Secretary

ACS: 36190

Bhavesh Tanna

Director

DIN: 033534452

Tejas Deherkar

CFO



STATEMENT OF PROFIT AND LOSS

FOR YEAR ENDED 31ST MARCH 2021

(Amount in ₹)

Particulars	Note No.	Year ended 31-03-2021	Year ended 31-03-2020
INCOME			
Revenue from operations	21	11,99,05,799	-
Other income	22	46,02,656	42,96,300
TOTAL INCOME		12,45,08,455	42,96,300
EXPENSES			
Cost of Material Consumed	23	10,61,20,010	-
Employee benefits expense	24	11,82,500	7,01,800
Finance costs	25	8,77,543	6,83,326
Depreciation and amortization expense	3	6,16,284	6,16,284
Other expenses	26	73,84,771	9,94,157
Total expenses		11,61,81,108	29,95,566
Profit / (Loss) before tax		83,27,347	13,00,734
TAX EXPENSES			
- Current tax		22,08,298	2,12,028
- Earlier Year's Tax		2,965	9,334
- Deferred tax		(27,210)	(1,98,574)
Total tax expense		21,84,053	22,788
Profit / (loss) for the year		61,43,294	12,77,946
Other Comprehensive Income			
Items that will not be reclassified subsequently to profit or loss	-		
Gain/(Loss) on recognised on fair valuation of Financial Assets		11,99,450	(9,71,750)
Tax on above		(3,01,878)	2,42,653
		8,97,572	(7,29,098)
Total comprehensive income for the year		70,40,866	5,48,848
Earning per equity share Basic & Diluted EPS (in Rs.)	27	1.61	0.33

For Thanawala & Company

Chartered Accountants

Firm Registration No.:

CA Vijay Thanawala

Partner

Membership No.: 015632

Place: Mumbai

Date: 20th April 2021

For and Behalf of Board of Director

Laxmikant Kabra

Chairman

DIN: 00061346

Chintan Doshi

Company Secretary

ACS: 36190

Bhavesh Tanna

Director

DIN: 033534452

Tejas Deherkar

CFO

STATEMENT OF CASH FLOW

FOR THE YEAR ENDED 31ST MARCH 2021

(Amount in ₹)

Particulars	Year ended 31-03-2021	Year ended 31-03-2020
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (loss) / profit before tax	83,27,347	13,00,734
Adjustments for		
Depreciation and Amortization Expense	6,16,284	6,16,284
Profit on Sales of Investments		(5,14,880)
Dividend Income	-	(2,31,285)
Finance Costs	8,77,543	6,83,326
Interest Income classified as investing cash flow	(35,79,401)	-
Operating profit before working capital changes	62,41,773	18,54,178
Working capital adjustments: -		
Increase / (Decrease) in Trade and Other Payables	1,89,47,301	2,951
Increase / (Decrease) in Provisions	28,73,162	46,000
Increase / (Decrease) in Other current Liabilities	-	(1,35,000)
Increase / (Decrease) in Other Financial Liabilities	2,33,577	54,533
(Increase) / Decrease in Inventories	(6,35,037)	-
(Increase) / Decrease in Trade Receivables	(3,41,47,344)	8,47,500
(Increase) / Decrease in Other Financial Assets	(3,43,10,361)	29,47,500
(Increase) / Decrease in Other Current Assets	51,483	22,14,404
Cash generated from / (used in) operations	(4,07,45,447)	78,32,067
Direct taxes paid (Net of Refunds)	(18,14,842)	(1,26,424)
Net cash (used in) /from generated from operating activities	(4,25,60,289)	77,05,643
B. CASH FLOW FROM INVESTING ACTIVITIES		
Sale of Investments	40,25,000	1,57,90,000
Income from dividend	-	2,31,285
Loans and Advances	(26,49,650)	(2,16,62,298)
Short Term Advances	-	(8,36,600)
Interest Income	35,79,401	-
Net cash (used in) / generated from investing activities	49,54,751	(64,77,613)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of shares	6,33,99,600	-
Interest paid	(8,77,543)	(6,83,326)
Repayment of long-term borrowings (net)	1,56,27,198	(6,19,196)
Net cash (used in) / from financing activities	7,81,49,256	(13,02,522)
Net decrease in cash and cash equivalents (A+B+C)	4,05,43,718	(74,492)
Cash and cash equivalents at the beginning of the year	1,76,453	2,50,946
Cash and cash equivalents at the end of the year	4,07,20,171	1,76,454

For Thanawala & Company
Chartered Accountants
Firm Registration No.:

CA Vijay Thanawala
Partner
Membership No.: 015632

Place: Mumbai
Date: 20th April 2021

For and Behalf of Board of Director

Laxmikant Kabra
Chairman
DIN: 00061346

Chintan Doshi
Company Secretary
ACS: 36190

Bhavesh Tanna
Director
DIN: 033534452

Tejas Deherkar
CFO



STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31ST MARCH 2021

EQUITY SHARE CAPITAL:	Balance as on 31 st March 2020	Changes during the year	Balance as on 31 st March 2021
Paid up Capital	3,82,00,000	-	3,82,00,000

(Amount in ₹)

OTHER EQUITY:	Reserves and Surplus		
Particulars	Share Premium Account	Retained Earnings	Total
Balance as on 31 st March 2020	1,20,00,000	40,85,288	1,72,90,923
Profit/(Loss) for the year	-	61,43,294	61,43,294
Items of Other Comprehensive Income for the year, net of tax:	-	8,97,572	8,97,572
Balance as on 31st March 2021	1,20,00,000	1,11,26,154	2,31,26,154



NOTES TO THE FINANCIAL STATEMENT

AS ON 31 MARCH 2021

1. Corporate Information

Eiko LifeSciences Limited (Formerly known as Narendra Investments (Delhi) Limited) (the Company) is a company registered under Companies Act, 2013 and incorporated on 7th January 1977. The company's activities primarily comprise of manufacturing of Speciality and Fine Chemicals. The shares of company are listed on the BSE. The registered office of the company is located at 604, Centrum, opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane West - 400 604

2A. Basis of preparation

The Statement of Assets and Liabilities of the Company as of March 31, 2021, and the Statement of Profit and Loss, the Statement of Cash flows and the Statement of Changes in Equity for the year ended March 31, 2021, has been prepared under Indian Accounting Standards ('Ind AS') notified under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015. The financial Statement as at and for the year March 31, 2021, along with financial statement as at and for the year ended March 31, 2020

Accounting Estimates

The preparation of the financial statements, in conformity with the Ind AS, requires the management to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities and disclosure of contingent liabilities as at the date of financial statements and the results of operation during the reported period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates which are recognized in the period in which they are determined.

Estimates and assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, which have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. The Company based its assumptions and estimates on parameters available when the financial statements were prepared. Existing

circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

2B. Significant accounting policies

A. Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.

An asset/ liability is treated as current when it is:

- Expected to be realized/ settled or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realized/ settled within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets/ liabilities are classified as non-current.

The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Company has identified twelve months as its operating cycle. Deferred tax assets and liabilities are classified as non-current assets and liabilities.

B. Fair value measurement

The Company's accounting policies and disclosures require the measurement of fair values for, both financial and non-financial assets and liabilities. The Company has an established control framework with respect to the measurement of fair values. The management regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as broker quotes or pricing services, is used to measure fair values, then the management assesses the evidence obtained from the third parties to support the conclusion that such valuations meet the requirements of Ind AS, including the level in the fair value hierarchy in which such valuations should be classified.



When measuring the fair value of a financial asset or a financial liability, the Company uses observable market data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

C. Property, Plant and Equipment

An item of property, plant and equipment that qualifies as an asset is measured on initial recognition at cost. Following initial recognition, items of property, plant and equipment are carried at its cost less accumulated depreciation and accumulated impairment losses.

The Company identifies and determines cost of each part of an item of property, plant and equipment separately, if the part has a cost which is significant to the total cost of that item of property, plant and equipment and has useful life that is materially different from that of the remaining item.

The cost of an item of property, plant and equipment comprises of its purchase price including import duties and other nonrefundable purchase taxes or levies, directly attributable cost of bringing the asset to its working condition for its intended use and the initial estimate of decommissioning, restoration and similar liabilities, if any. Any trade discounts and rebates are deducted in arriving at

the purchase price. Cost includes cost of replacing a part of a plant and equipment if the recognition criteria are met. Expenses directly attributable to new plant and equipment during its construction period are capitalized if the recognition criteria are met. Expenditure related to plans, designs and drawings of buildings or plant and machinery is capitalized under relevant heads of property, plant, and equipment if the recognition criteria are met.

Capital work in progress and Capital advances:

Cost of assets not ready for intended use, as on the balance sheet date, is shown as capital work in progress. Advances given towards acquisition of fixed assets outstanding at each balance sheet date are disclosed as Other Non-Current Assets.

Depreciation/ Amortization:

- a. Depreciation on tangible assets is provided on straight line basis considering the useful lives prescribed in Schedule II to the Act on a pro-rata basis.
- b. Leasehold improvements are amortized based on primary lease period or their useful lives prescribed under Schedule -II, whichever is lower.
- c. The asset's useful lives are reviewed and adjusted, if appropriate, at the end of each reporting period.
- d. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.
- e. The residual values, useful lives, and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

Derecognition:

The carrying amount of an item of property, plant and equipment is derecognized on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the Derecognition of an item of property, plant and equipment is measured as the difference between the net disposal proceeds and the carrying amount of the item and is recognized in the Statement of Profit and Loss when the item is derecognized.



D. Intangible assets

Measurement at recognition:

Intangible assets acquired separately are measured on initial recognition at cost. Intangible assets arising on acquisition of business are measured at fair value as at date of acquisition. Internally generated intangibles including research cost are not capitalized and the related expenditure is recognized in the Statement of Profit and Loss in the period in which the expenditure is incurred. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment loss, if any. Assets acquired but not ready for use are classified under Capital work-in-progress or intangible assets under development.

Amortization:

Intangible Assets with finite lives are amortized on a Straight-Line basis over the estimated useful economic life. The amortization expense on intangible assets with finite lives is recognized in the Statement of Profit and Loss.

Intangible assets with indefinite useful lives, are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. The impairment loss on intangible assets with indefinite life is recognized in the Statement of Profit & Loss.

Impairment:

An impairment loss is recognized whenever the carrying amount of an asset or its cash generating unit (CGU) exceeds its recoverable amount. The recoverable amount of an asset is the greater of its fair value less cost to sell and value in use. To calculate value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market rates and the risk specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the CGU to which the asset belongs. Fair value less cost to sell is the best estimate of the amount obtainable from the sale of an asset in an arm's length transaction between knowledgeable, willing parties, less the cost of disposal.

Impairment losses, if any, are recognized in the Statement of Profit and Loss and included in depreciation and amortization expense. Impairment losses, on assets other than goodwill are reversed in the Statement of Profit and Loss only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined if no impairment loss had previously been recognized.

E. Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial instruments also include derivative contracts such as foreign currency foreign exchange forward contracts.

Financial instruments also cover contracts to buy or sell a non-financial item that can be settled net in cash or another financial instrument, or by exchanging financial instruments, as if the contracts were financial instruments, except for contracts that were entered into and continue to be held for the purpose of the receipt or delivery of a non-financial item in accordance with the entity's expected purchase, sale or usage requirements.

Derivatives are currently recognized at fair value on the date on which the derivative contract is entered into and are subsequently re-measured to their fair value at the end of each reporting period.

Classification

A Financial instrument is any contract that gives rise to a financial asset of one entity and financial liability or equity instruments of another entity.

Financial assets, other than equity, are classified into, financial assets at fair value through other comprehensive income (FVOCI) or fair value through profit and loss account (FVTPL) or at amortised cost. Financial assets that are equity instruments are classified as FVTPL or FVOCI. Financial liabilities are classified as amortised cost category and FVTPL.

Business Model assessment and Solely payments of principal and interest (SPPI) test:

Classification and measurement of financial assets depends on the business model and results of SPPI test. The Company determines the business model at a level that reflects how groups of financial assets are managed together to achieve



a business objective. This assessment includes judgement reflecting all relevant evidence including-

- How the performance of the business model and the financial assets held within that business model are evaluated and reported to the entity's key management personnel
- The risks that affect the performance of the business model (and the financial assets held within that business model) and the way those risks are managed
- How managers of the business are compensated (for example, whether the compensation is based on the fair value of the assets managed or on the contractual cash flows collected)
- The expected frequency, value and timing of sales are also important aspects of the Company's assessment.

If cash flows after initial recognition are realised in a way that is different from the Company's original expectations, the Company does not change the classification of the remaining financial assets held in that business model but incorporates such information when assessing newly originated or newly purchased financial assets going forward.

Initial recognition and measurement

The classification of financial instruments at initial recognition depends on their contractual terms and the business model for managing the instruments.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at FVTPL) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognised immediately in the Statement of profit or loss.

Financial assets and financial liabilities, except for loans, debt securities and deposits are recognised on the trade date i.e., when a Company becomes a party to the contractual provisions of the instruments. Loans, debt securities and deposits are recognised when the funds are

transferred to the customer's account. Trade receivables are measured at the transaction price.

Subsequent measurement

a. Financial assets at amortized cost

Financial assets having contractual terms that give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding and that are held within a business model whose objective is to hold such assets in order to collect such contractual cash flows are classified in this category. Subsequently these are measured at amortised cost using effective interest method less any impairment losses.

b. Debt Instruments at FVOCI

Debt instruments that are measured at FVOCI have contractual terms that give rise on specified dates to cash flows that are solely payments of principal and interest on principal outstanding and that are held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets. These instruments largely comprise long-term investments made by the Company. FVOCI debt instruments are subsequently measured at fair value with gains and losses arising due to changes in fair value recognised in OCI. Interest income and gains and losses are recognised in profit or loss in the same manner as for financial assets measured at amortised cost. On derecognition, cumulative gains or losses previously recognised in OCI are reclassified from OCI to profit or loss.

c. Equity Instruments at FVOCI

These include financial assets that are equity instruments as defined in Ind AS 32 "Financial Instruments: Presentation" and are not held for trading and where the Company's management has elected to irrevocably designated the same as Equity instruments at FVOCI upon initial recognition. Subsequently, these are measured at fair value and changes therein are recognised directly in other comprehensive income, net of applicable income taxes.

Gains and losses on these equity instruments are never recycled to profit or loss.

Dividends from these equity investments are recognised in the statement of profit and loss when the right to receive the payment has been established. Fair value through Profit and loss account financial assets are measured at FVTPL



unless it is measured at amortised cost or at FVOCI on initial recognition. The transaction costs directly attributable to the acquisition of financial assets at fair value through profit or loss are immediately recognised in profit or loss.

d. Derivatives recorded at fair value through P&L

The Company transact in derivative financial instruments which are in the nature of covered call option contracts. Such derivative financial instruments are initially recognised at fair value on the date on which the derivative contract is entered into and are subsequently re-measured at their fair value at the end of each reporting period. Derivatives are classified as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. Any gains or losses arising from changes in the fair value of such derivative financial instruments are taken directly to statement of profit and loss and included in net gain on fair value changes. The Company has not designated any derivative instruments as a hedging instrument.

e. Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all its liabilities. Equity instruments are recorded at the proceeds received, net of direct issue costs.

f. Other Financial Liabilities

These are measured at amortised cost using effective interest rate.

g. Derecognition of Financial assets and liabilities:

The Company derecognizes a financial asset only when the contractual rights to the cash flows from the asset expires or it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity.

A financial liability is derecognised when the obligation under the liability is discharged, cancelled, or expires.

h. Impairment of financial assets

The Company recognizes a loss allowance for expected credit losses on a financial asset that is at amortized cost or fair value through OCI. Loss allowance in respect of financial assets is measured at an amount equal to lifetime expected credit losses and is calculated as the difference between their carrying amount and the present value of the expected future cash flows discounted at the original effective interest rate.

F. Reclassification of Financial assets

The company does not re-classify its financial assets subsequent to their initial recognition, apart from the exceptional circumstances when the company changes its business model for managing such financial assets. The company does not re-classify its financial liabilities.

G. Investment in subsidiaries and associates

The company has chosen to carry the Investments in associates and subsidiaries at cost less impairment, if any in the separate financial statements.

H. Provision and Contingent liabilities

Provisions

A provision is recognized when the Company has a present obligation (legal or constructive) as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value (except where time value of money is material) and are determined based on the best estimate required to settle the obligation at the reporting date when discounting is used, the increase in provision due to passage of time is recognized as finance cost. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases, where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements unless the probability of outflow of resources is remote.

Provisions, contingent liabilities, contingent assets, and commitments are reviewed at each balance sheet date.

I. Inventories

Raw materials and stores, work in progress, traded and finished goods are stated at the lower of cost and net realizable value. Cost of raw materials and traded goods



comprises cost of purchases. Cost of work in progress and finished goods comprises direct materials, direct labour and an appropriate proportion of variable and fixed overhead expenditure, the latter being allocated based on normal operating capacity. Cost of inventories also include all other costs incurred in bringing the inventories to their present location and condition. Cost includes the reclassification from equity of any gains or losses on qualifying cash flow hedges relating to purchases of raw material but excludes borrowing costs. Costs are assigned to individual items of inventory based on weighted average price. Costs of purchased inventory are determined after deducting rebates and discounts. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

J. Cash and cash equivalents

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

K. Revenue:

Sale of goods:

Revenue from operations comprises of sales of goods after the deduction of discounts, goods and service tax and estimated returns. Discounts given by the Company includes trade discounts, volume rebates and other incentive given to the customers. Accumulated experience is used to estimate the provision for discounts. Revenue is only recognized to the extent that it is highly probable a significant reversal will not occur.

Revenue from the sale of goods is recognized when control of the goods has transferred to our customer and when there are no longer any unfulfilled obligations to the customer, this is generally when the goods are delivered to the customer depending on individual customer terms, which can be at the time of dispatch or delivery. This is considered the appropriate point where the performance obligations in our contracts are satisfied as the Company no longer have control over the inventory.

Our customers have the contractual right to return goods only when authorized by the Company. Estimation is made of goods that will be returned and a liability is recognized for that amount. An asset is also recorded for the

corresponding inventory that is estimated to return to the Company using a best estimate based on accumulated experience.

Interest Income:

For all financial instruments measured at amortised cost, interest income is recorded using the effective interest rate (EIR), which is the rate that discounts the estimated future cash payments or receipts through the expected life of the financial instruments or a shorter period, where appropriate, to the net carrying amount of the financial assets. Interest income is included in other income in the Statement of Profit and Loss.

Dividend Income

Dividend income is recognised only when the right to receive the same is established, it is probable that the economic benefits associated with the dividend will flow to the Company, and the amount of dividend can be measured reliably.

L. Foreign Currency

Transaction and Balances:

Transactions in foreign currencies are translated into the respective functional currencies of the Company at the exchange rates at the dates of the transactions or an average rate if the average rate approximates the actual rate at the date of the transaction. Foreign currency transactions are recorded on initial recognition in the functional currency, using the exchange rate at the date of the transaction. At each balance sheet date, foreign currency monetary items are reported using the closing exchange rate. Exchange differences that arise on settlement of monetary items or on reporting at each balance sheet date of the Company's monetary items at the closing rate are recognized as income and expenses in the period in which they arise.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of transactions. Non-monetary items that are measured at fair value in a foreign currency shall be translated using the exchange rates at the date when the fair value was measured. Exchange differences are generally recognized in the Statement of Profit and Loss.



M. Employee Benefits

Short Term Benefits:

Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Other long-term employee benefit obligations:

The liabilities for earned leave are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. They are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. The benefits are discounted using the market yields at the end of the reporting period that have terms approximating to the terms of the related obligation. Remeasurements because of experience adjustments and changes in actuarial assumptions are recognized in profit or loss.

Post-Employment Obligations:

a. Gratuity

The Company's net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets.

The calculation of defined benefit obligations is performed annually by a qualified actuary using the projected unit credit method. When the calculation results in a potential asset for the Company, the recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan.

Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur, directly in other comprehensive income. They are included in retained earnings in the statement of changes in equity and in the balance sheet.

b. Defined Benefit contribution plan

The Company pays provident fund contributions to publicly administered provident funds as per local regulations. The

Company has no further payment obligations once the contributions have been paid. The contributions are accounted for as defined contribution plans and the contributions are recognized as employee benefit expense when they are due.

c. Bonus Plan

The Company recognizes a liability and an expense for bonuses. The Company recognizes a provision where contractually obliged or where there is a past practice that has created a constructive obligation.

N. Taxes

Current Tax

Current tax is the amount of tax payable (recoverable) in respect of the taxable profit / (tax loss) for the year determined in accordance with the provisions of the Income-Tax Act, 1961. Current income tax for current and prior periods is recognized at the amount expected to be paid to or recovered from the tax authorities, using tax rates and tax laws that have been enacted or substantively enacted at the reporting date.

Current tax assets and liabilities are offset only if, the Company:

- has a legally enforceable right to set off the recognized amounts; and
- intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognized for all taxable temporary differences except:

- When the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.
- In respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future



Deferred tax assets (including MAT credit) are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilized except:

- When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- In respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

The carrying amount of deferred tax assets (including MAT credit available) is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Deferred tax relating to items recognized outside profit or loss is recognized outside the statement of profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognized in correlation to the underlying transaction either in OCI or directly in equity. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

The Company recognizes MAT credit available as an asset only to the extent that there is convincing evidence that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. In the year in which the Company recognizes MAT credit as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternative Tax under the Income-tax Act, 1961, the said asset is created by way of credit to the statement of profit and loss and shown as “MAT Credit Entitlement.” The Company reviews the “MAT credit entitlement” asset at each reporting date and writes down the asset to the extent the Company does not have convincing evidence that it will pay normal tax during the specified period.

GST paid on acquisition of assets or on incurring expenses. Expenses and assets are recognized net of the amount of GST (Goods and Service Tax) paid, except:

- When the tax incurred on a purchase of assets or services is not recoverable from the taxation authority, in which case, the tax paid is recognized as part of the cost of acquisition of the asset or as part of the expense item, as applicable
- When receivables and payables are stated with the amount of tax included the net amount of tax recoverable from, or payable to, the taxation authority is included as part of other current assets or liabilities in the balance sheet.

O. Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset until such time that the asset is substantially ready for their intended use. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

P. Earnings per share

Basic and diluted earnings per Equity Share are computed in accordance with Indian Accounting Standard 33 ‘Earnings per Share’, notified accounting standard by the Companies



(Indian Accounting Standards) Rules of 2015 (as amended). Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of shares outstanding during the period. The weighted average number of equity shares outstanding during the period is

adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

NOTE 3: PROPERTY, PLANT & EQUIPMENT

Property, Plant & Equipment		
Gross Value	Vehicles	Total
As of 31st Mar, 2020	51,51,000	51,51,000
Additions	-	-
Disposal / Transfer	-	-
As of 31st Mar, 2021	51,51,000	51,51,000
Accumulated Depreciation / Amortization		
As of 31st Mar, 2020	20,59,863	14,43,579
Charge for the year	6,16,284	6,16,284
Disposal / Transfer	-	-
As of 31st Mar, 2021	26,76,147	20,59,863
Net Book Value		
As of 31st Mar, 2020	30,91,137	37,07,421
As of 31st Mar, 2021	24,74,853	24,74,853

NOTE 4: NON-CURRENT INVESTMENTS

Particulars	As at 31st March, 2021 (₹)			As at 31st March, 2020 (₹)		
	Face value	No. of Shares	Amount	Face Value	No. of Shares	Amount
A) Subsidiaries						
Fudkor India Private Limited		-	-	10	25,500	38,25,000
Vegico Foods Private Limited		-	-	10	10,000	2,00,000
B) Others						
Investment in Quoted Shares						
Aspinwal & Co. Ltd.	10	11,500	22,95,930	10	11,500	22,95,930
Investment in Un-quoted Shares						
Shivshayadri Pathpethi Ltd.	100	5	550	100	5	550
Total			22,96,480			63,21,480



Particulars	As on 31.03.2021	As on 31.03.2020
Aggregate book value of the Quoted Investments	22,95,930	22,95,930
Aggregate book value of the Unquoted Investments	550	550
Aggregate market value of the Quoted Investments	21,94,200	9,94,750

NOTE 5: LOANS (NON-CURRENT)

Unsecured, Considered Good

Particulars	As at 31-03-2021	As at 31-03-2020
Loan to Inter Corporate	1,28,65,612	1,28,65,612
Loan to others	2,32,49,650	2,06,00,000
	3,61,15,262	3,34,65,612

NOTE 6: OTHER FINANCIAL ASSETS

Particulars	As at 31-03-2021	As at 31-03-2020
Long Term Deposits with Banks	1,80,97,700	1,45,30,962
	1,80,97,700	1,45,30,962

NOTE 7: INVENTORIES

Particulars	As at 31-03-2021	As at 31-03-2020
At Lower of Cost or Net Realizable Value		
Raw Materials	6,35,037	-
	6,35,037	-

NOTE 8: TRADE RECEIVABLES

Particulars	As at 31-03-2021	As at 31-03-2020
Trade Receivables		
- overdue for more than six months	-	-
- others	3,41,47,344	-
	3,41,47,344	-

NOTE 9: CASH AND CASH EQUIVALENTS

Particulars	As at 31-03-2021	As at 31-03-2020
Balance with Banks		
- in current accounts	20,00,055	1,66,258
- In Escrow Account	3,87,12,271	
Cash on hand	7,845	10,196
	4,07,20,171	1,76,454

NOTE 10: OTHER CURRENT FINANCIAL ASSETS

Particulars	As at 31-03-2021	As at 31-03-2020
FDR With ICICI Bank - Pref Allotment	2,47,22,950	-
Duty Drawback Receivable	36,378	-
Interest Accrued but not due	-	7,12,475
Balances with government authorities	67,59,422	62,652
	3,15,18,750	7,75,127

NOTE 11: OTHER CURRENT ASSETS

Particulars	As at 31-03-2021	As at 31-03-2020
Prepaid Expenses	-	51,483
	-	51,483

NOTE NO. 12: EQUITY SHARE CAPITAL

Particulars	As at 31 March 2021		As at 31 March 2020	
	No. of Shares	Amount	No. of Shares	Amount
Share Capital				
Authorized Capital				
At the beginning of the Year	50,00,000	5,00,00,000	50,00,000	5,00,00,000
Additions During the Year	50,00,000	5,00,00,000	-	-
	1,00,00,000	10,00,00,000	50,00,000	5,00,00,000
Issues, Subscribed and Paid up:				
Equity Shares of Rs.10/- each.	38,20,000	3,82,00,000	38,20,000	3,82,00,000
Total	38,20,000	3,82,00,000	38,20,000	3,82,00,000

Issued, Subscribed and Paid-up capital	As of 31 st March, 2021		As of 31 st March, 2020	
	No. of Shares	Amount (Rs.)	No. of Shares	Amount (Rs.)
At the beginning of the Year	38,20,000	3,82,00,000	30,20,000	3,02,00,000
Share issued during the Year	-	-	8,00,000	80,00,000
Issued, Subscribed and Paid-Up capital at the end of year	38,20,000	3,82,00,000	38,20,000	3,82,00,000

Terms/rights attached to equity shares

The company has only one class of equity shares having par value of Rs. 10 per share. Each holder of equity shares is entitled to one vote per share.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive any of the remaining assets of the company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

Details of Share Holders holding more than 5% shares in the company

Name of Shareholder	As at 31 March 2021		As at 31 March 2020	
	No. of Share	Shareholding	No. of Share	Shareholding
Devrath Bakebihari Choursya	4,00,000	10.47%	4,00,000	10.47%
Finsage Capital Service Pvt. Ltd.	4,34,009	11.36%	4,30,000	11.26%
Sunil Kanaiyalal Pagrani	27,440	0.72%	4,38,000	11.47%
Bhavesh Tanna	2,02,000	5.29%	99,140	2.60%
Svaks Biotech India Private Limited	2,11,000	5.52%	-	-
Lenus Finvest Private Limited	5,54,414	14.51%	1,00,000	2.62%

NOTE NO. 13: OTHER EQUITY

Particulars	As at 31-03-2021	As at 31-03-2020
RESERVE AND SURPLUS		
Share Premium Account		
Opening Balance	1,20,00,000	1,20,00,000
Add: Addition	-	-
Closing Balance	1,20,00,000	1,20,00,000
Profit & Loss Account		
Opening Balance	46,20,643	40,71,795
Add: Profit for the year	61,43,294	12,77,946
Items of Other Comprehensive Income for the year, net of tax:	8,97,572	-7,29,098
Closing Balance	1,16,61,509	46,20,643
Total	2,36,61,509	1,66,20,643

NOTE NO. 14: SHARE APPLICATION MONEY PENDING FOR ALLOTMENT

Particulars	As on 31 st March, 2021		As on 31 st March, 2020	
	No. of Shares	Amount (₹)	No. of Shares	Amount (₹)
Share Application Money Pending for Allotment	63,39,960	6,33,99,600	-	-
	63,39,960	6,33,99,600	-	-

NOTE 15: NON-CURRENT BORROWINGS

Particulars	As at 31-03-2021	As at 31-03-2020
Secured Loans		
Term Loans		
From Banks	1,75,86,674	19,59,475
	1,75,86,674	19,59,475

Note: Vehicle Loan from HDFC Bank is secured by way of hypothecation of the car. The rate of interest is 9.25% P.A.



Repayment Schedule

Financial Year	Amount
2021-22	6,79,090
2022-23	7,44,477
2023-24	5,35,908

NOTE 16: DEFERRED TAX LIABILITIES

Particulars	As at 31-03-2021	As at 31-03-2020
Timing Difference on tangible assets	(3,104)	41,535
Deferred Tax Liability on Investments	(25,603)	(3,27,481)
Deferred Tax Liability on Others	(2,07,810)	(2,25,239)
Deferred Tax (Asset)/Liability	(2,36,517)	(5,11,185)

NOTE 17: TRADE PAYABLES

Particulars	As at 31-03-2021	As at 31-03-2020
Due to Others	1,89,50,252	2,951
	1,89,50,252	2,951.00

₹64,44,024/- is outstanding as on March 31, 2021, to Micro, small and medium enterprises on account of principal or interest (March 31, 2020: Nil)

NOTE 18: OTHER CURRENT LIABILITIES

Particulars	As at 31-03-2021	As at 31-03-2020
Current Maturities for Long Term Borrowing	6,79,090	6,19,196
Duties & Taxes	30,683	-
Salary Payable	1,43,000	
	8,52,773	6,19,196

NOTE 19: PROVISIONS

Particulars	As at 31-03-2021	As at 31-03-2020
Provision for Audit Fees	30,000	60,000
Provision for Expenses	29,69,162	66,000
	29,99,162	1,26,000

NOTE 20: CURRENT TAX LIABILITIES

Particulars	As at 31-03-2021	As at 31-03-2020
Current Tax Liabilities	4,90,415	93,994
	4,90,415	93,994


NOTE 21: REVENUE FROM OPERATIONS

Particulars	Year ended 31-03-2021	Year ended 31-03-2020
Sale of Products		-
Local Sale	7,55,49,405	-
Export Sale	4,40,14,030	
Other Operating revenues		
Freight, Insurance on Export Sale	3,40,414	-
Freight, Insurance on Domestic Sale	1,950	-
	11,99,05,799	-

NOTE 22: OTHER INCOME

Particulars	Year ended 31-03-2021	Year ended 31-03-2020
Profit on sale of Investments	-	5,14,880
Dividend	-	2,31,285
Interest Income	35,79,641	35,50,135
Realised/ Unrealized Forex Loss and Gain	5,04,100	-
Duty Drawback	5,18,915	-
	46,02,656	42,96,300

NOTE 23: COST OF MATERIAL CONSUMED

Particulars	Year ended 31-03-2021	Year ended 31-03-2020
Opening Stock of Raw Materials		
Add: Purchase of Raw Materials	10,67,55,047	
Less: Closing Stock of Raw Materials	(6,35,037)	
	10,61,20,010	-

NOTE 24: EMPLOYEE BENEFITS EXPENSE

Particulars	Year ended 31-03-2021	Year ended 31-03-2020
Salaries and wages	11,82,500	7,01,800
	11,82,500	7,01,800

NOTE 25: FINANCE COSTS

Particulars	Year ended 31-03-2021	Year ended 31-03-2020
Interest on:		
- Term Loans & Cash Credit	8,77,543	6,83,326
	8,77,543	6,83,326

NOTE 26: OTHER EXPENSES

Particulars	Year ended 31-03-2021	Year ended 31-03-2020
Bank Charges	12,978	2,614
Advertisement	46,154	55,800
BSE Annual Fees Filing	4,45,000	3,00,000
Traveling and conveyance	-	88,545
ROC Charges	4,96,222	11,400
Legal, Professional & Consultancy Charges	81,860	1,58,000
Insurance Charges	73,984	77,716
Registrar Charges	10,000	19,167
Courier and Postage	3,068	42,826
Miscellaneous Expenses	1,08,395	13,000
NSDL and CDSL Charges	42,565	19,000
Conference and Meeting Exp	94,635	1,31,294
Printing & Stationary	22,582	44,795
Audit Fees	30,000	30,000
Commission Expenses	7,00,000	
Electricity Expenses	2,15,388	-
Repairs & maintenance Charges	1,41,000	-
Clearing & Forwarding Charges	3,68,771	-
Processing Charges	14,95,125	-
Other Factory Overheads	29,01,832	-
Transportation Charges	95,212	-
	73,84,771	9,94,157

NOTE 27: EARNING PER SHARE

Particulars	As at 31-03-2021	As at 31-03-2020
Profit attributable to equity shareholders for basics & Diluted EPS	61,43,294	12,77,946
Less: Profit attributable to Preference Shareholders	-	-
Profit attributable to Equity Shareholders	61,43,294	12,77,946
Weighted average number of Equity Shares:		
-Basic	38,20,000	38,20,000
-Diluted	38,20,000	38,20,000
Earnings per Share		
-Basic	1.61	0.33
-Diluted	1.61	0.33

Note: Financial instruments

The fair value of the financial assets is included at amounts at which the instruments could be exchanged in a current transaction between willing parties other than in a forced or liquidation sale.

The following methods and assumptions were used to estimate the fair value:

- Fair value of cash and short-term deposits, trade and other short-term receivables, trade payables, other current liabilities, approximate their carrying amounts largely due to the short-term maturities of these instruments



- b) Financial instruments with fixed and variable interest rates are evaluated by the Company based on parameters such as interest rates and individual credit worthiness of the counterparty. Based on this evaluation, allowances are taken to account for the expected losses of these receivables.

NOTE 28: RELATED PARTY

Party	Relationship
Urvi Speciality Chemicals	Partnership firm of director
Key Management Person	
Laxmikant Ramprasad Kabra	Chairman, Non-Executive Non- Independent Director
Bhavesh Tanna	Executive Director
Mandar Patil	Non-Executive - Independent Director
Kajal Kothari	Non-Executive - Independent Director
Rajkumar Baheti	Non-Executive - Independent Director
Umesh More	Executive Director
Tejas Deherkar	Chief Financial Officer
Chinatn Doshi	Company Secretary and Compliance Officer

Nature of transaction	As at 31.03.2021	As at 31.03.2020
Transactions with related parties		
Salary		
Chintan Doshi	1,80,000	1,80,000
Tejas Deherkar	2,60,000	1,44,000
Processing Charges		
Urvi Speciality Chemicals	13,50,000	-

NOTE 29: FINANCIAL RISK MANAGEMENT

The Company's financial risk management is an integral part of how to plan and execute its business strategies. The Company's financial risk management policy is set by the managing board. The details of different types of risk and management policy to address these risks are listed below:

1. Market Risk-

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from a change in the price of a financial instrument. The value of a financial instrument may change as a result of changes in the interest rates, foreign currency exchange rates, equity prices and other market changes that affect market risk sensitive instruments. Market risk is attributable to all market risk sensitive financial instruments including investments and deposits, foreign currency receivables, payables and loans and borrowings. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs

1.1. Market Risk - Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows of the financial instruments will fluctuate because of changes in market interest rates. The company's exposure to the risk of changes in market interest rates primarily to the Company's borrowings, both short term and long-term obligations with floating interest rates.



The company is also exposed to interest rate risk on its financial assets that include fixed deposits (which are part of cash and cash equivalents) since all these are generally for short durations, there is no significant interest rate risks pertaining to these deposits

Sensitivity analysis to interest rate risk

The company doesn't account for any fixed rate financial assets or financial liabilities at fair value through profit or loss. Therefore, a change in interest rates at the reporting date would not affect profit or loss.

1.2. Market Risk - Price Risk

The Company does make deposit with the banks to provide security against guarantee issued by bank to company's trade payables. Deposit is made in fixed rate instrument. In view of this it is not susceptible to market price risk, arising from changes in interest rates or market yields which may impact the return and value of the investments.

1.3. Market Risk - Currency Risk

The fluctuation in foreign currency exchange rates may have a potential impact on the statement of profit and loss and equity, where any transaction references more than one currency or where assets/liabilities are denominated in a currency other than the functional currency of the Company. The functional currency of the company is Indian Rupees. The Company follows a natural hedge driven currency risk mitigation policy to the extent possible. However, for year ended 31st March 2021, company is not exposed to currency risk on account of its trade payables in foreign currency.

2. Credit Risk

Credit Risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's receivables from customers. The carrying amount of Financial Assets represents the maximum credit exposure.

Trade Receivables

The Company has established a credit policy under which each new customer is analyzed individually for creditworthiness before the payment and delivery terms and conditions are offered. The Company's review includes external ratings, if they are available, financial statements, industry information, business intelligence and in some cases bank references.

Trade Receivables of the Company are typically unsecured, except to the extent of the security deposits received from the customers or financial guarantees provided by the market organizers in the business. Credit Risk is managed through credit approvals and periodic monitoring of the creditworthiness of customers to which the Company grants credit terms in the normal course of business. The Company performs ongoing credit evaluations of its customers' financial condition and monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. The Company has no concentration of Credit Risk as the customer base is geographically distributed in India and outside India.

Expected credit loss for trade receivable:

The allowance for impairment of Trade receivables is created to the extent and as and when required, based upon the expected collectability of accounts receivables. On account of adoption of Ind AS 109, the Company uses lifetime Expected Credit Loss (ECL) model for assessing the impairment loss. For this purpose, the Company uses a provision matrix to compute the expected credit loss amount for trade receivables. Loss rates are based on actual credit loss experience and past trends. The provision matrix takes into account external and internal credit risk factors and historical experience / current facts available in relation to defaults and delays in collection thereof.



Other Financial Assets

The company maintains its Cash and Cash equivalents and Bank deposits with banks having good reputation, good past track record and high-quality credit rating and also reviews their creditworthiness on an on-going basis.

3. Liquidity Risk

Liquidity Risk is the risk that the Company will face in meeting its obligation associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach in managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. Any short-term surplus cash generated, over and above the amount required for working capital and other operational requirements is retained as Cash and Cash Equivalents (to the extent required).

For Thanawala & Company

Chartered Accountants

Firm Registration No.:

CA Vijay Thanawala

Partner

Membership No.: 015632

Place: Mumbai

Date: 20th April 2021

For and Behalf of Board of Director

Laxmikant Kabra

Chairman

DIN: 00061346

Chintan Doshi

Company Secretary

ACS: 36190

Bhavesh Tanna

Director

DIN: 033534452

Tejas Deherkar

CFO